0001493152-19-010490.txt : 20190711 0001493152-19-010490.hdr.sgml : 20190711 20190711080118 ACCESSION NUMBER: 0001493152-19-010490 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20190531 FILED AS OF DATE: 20190711 DATE AS OF CHANGE: 20190711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novo Integrated Sciences, Inc. CENTRAL INDEX KEY: 0001138978 STANDARD INDUSTRIAL CLASSIFICATION: ENGINES & TURBINES [3510] IRS NUMBER: 593691650 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-109118 FILM NUMBER: 19950349 BUSINESS ADDRESS: STREET 1: 11120 NE 2ND STREET STREET 2: SUITE 200 CITY: BELLEVUE STATE: WA ZIP: 98004 BUSINESS PHONE: (206) 617-9797 MAIL ADDRESS: STREET 1: 11120 NE 2ND STREET STREET 2: SUITE 200 CITY: BELLEVUE STATE: WA ZIP: 98004 FORMER COMPANY: FORMER CONFORMED NAME: TURBINE TRUCK ENGINES INC DATE OF NAME CHANGE: 20010420 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended May 31, 2019

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______, 20___, to _____, 20___.

 

Commission File Number 333-109118

 

Novo Integrated Sciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   59-3691650
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification Number)

 

11120 NE 2nd Street, Suite 200

Bellevue, Washington

  98004
(Address of Principal Executive Offices)   (Zip Code)

 

(206) 617-9797

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on which Registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer,” “large accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
Non-accelerated filer [X] Smaller reporting company [X]
Emerging growth company [  ]    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes [  ] No [X]

 

There were 223,606,949 shares of the Registrant’s $0.001 par value common stock outstanding as of July 5, 2019.

 

 

 

  

 

 

Novo Integrated Sciences, Inc.

 

Contents

 

PART I – FINANCIAL INFORMATION 3
     
Item 1. Financial Statements 3
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation 18
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 22
     
Item 4. Controls and Procedures 23
     
PART II – OTHER INFORMATION 23
     
Item 1. Legal Proceedings 23
     
Item 1A. Risk Factors 23
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23
     
Item 3. Defaults Upon Senior Securities 23
     
Item 4. Mine Safety Disclosures 23
     
Item 5. Other Information 24
     
Item 6. Exhibits 24
     
Signatures 25

 

2
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of May 31, 2019 (unaudited) and August 31, 2018

 

   May 31, 2019   August 31, 2018 
    (unaudited)      
ASSETS          
Current Assets:          
Cash and cash equivalents  $2,478,303   $675,705 
Accounts receivable, net   1,383,029    1,337,545 
Other receivables, current portion   577,186    393,821 
Prepaid expenses and other current assets   149,718    161,838 
Total current assets   4,588,236    2,568,909 
           
Property and equipment, net   418,297    400,321 
Intangible assets   22,358,567    - 
Right-of-use assets   2,201,893    - 
Other receivables, net of current portion   85,043    57,352 
Acquisition deposits   1,445,495    1,112,404 
Goodwill   584,205    604,113 
TOTAL ASSETS  $31,681,736   $4,743,099 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts payable  $1,283,735   $1,307,599 
Accrued expenses   208,008    383,998 
Accrued interest (principally to related parties)   188,321    156,121 
Due to related parties   931,128    1,116,261 
Notes payable, current portion   369,750    382,350 
Debentures, related parties   1,183,664    - 
Operating lease liability, current portion   413,896    - 
Total current liabilities   4,578,502    3,346,329 
           
Debentures, related parties   -    1,224,000 
Operating lease liability, net of current portion   1,789,779    - 
TOTAL LIABILITIES   6,368,281    4,570,329 
           
Commitments and contingencies   -    - 
           
STOCKHOLDERS’ EQUITY          
Novo Integrated Sciences, Inc.          
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2019 and August 31, 2018          
Common stock; $0.001par value; 499,000,000 shares authorized; 223,585,536 and 207,881,743 shares issued and outstanding at May 31, 2019 and August 31, 2018   223,585    207,882 
Additional paid-in capital   35,695,491    10,053,683 
Other comprehensive income   1,102,188    1,139,815 
Accumulated deficit   (11,670,164)   (11,199,989)
Total Novo Integrated Sciences, Inc. stockholders’ equity   25,351,100    201,391 
Noncontrolling interest   (37,645)   (28,621)
Total stockholders’ equity   25,313,455    172,770 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $31,681,736   $4,743,099 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

3
 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three and Nine Months Ended May 31, 2019 and 2018 (unaudited)

 

   Three Months Ended   Nine Months Ended 
   May 31,   May 31,   May 31,   May 31, 
   2019   2018   2019   2018 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
Revenues  $2,489,575   $2,323,169   $7,001,607   $6,722,825 
                     
Cost of revenues   1,556,865    1,417,999    4,305,688    4,133,288 
                     
Gross profit   932,710    905,170    2,695,919    2,589,537 
                     
Operating expenses:                    
Selling expenses   3,846    17,900    33,085    86,640 
General and administrative expenses   991,992    1,064,107    3,020,001    3,978,861 
Total operating expenses   995,838    1,082,007    3,053,086    4,065,501 
                     
Loss from operations   (63,128)   (176,837)   (357,167)   (1,475,964)
                     
Non operating income (expense)                    
Interest income   4,090    120    13,473    331 
Interest expense   (41,735)   (42,696)   (136,643)   (480,981)
Total other income (expense)   (37,645)   (42,576)   (123,170)   (480,650)
                     
Loss before income taxes   (100,773)   (219,413)   (480,337)   (1,956,614)
                     
Income tax expense   -    -    -    - 
                     
Net loss  $(100,773)  $(219,413)  $(480,337)  $(1,956,614)
                     
Net loss attributed to noncontrolling interest   (1,515)   (1,515)   (10,162)   (6,871)
                     
Net loss attributed to Novo Integrated Sciences, Inc.  $(99,258)  $(217,898)  $(470,175)  $(1,949,743)
                     
Comprehensive loss:                    
Net loss   (100,773)   (219,413)   (480,337)   (1,956,614)
Foreign currency translation gain (loss)   (63,607)   (8,505)   (37,627)   (95,846)
Comprehensive loss:  $(164,380)  $(227,918)  $(517,964)  $(2,052,460)
                     
Weighted average common shares outstanding - basic and diluted   223,258,368    214,684,089    215,193,998    207,568,978 
                     
Net loss per common share - basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.01)

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

4
 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the Nine Months Ended May 31, 2019 and 2018 (unaudited)

 

                                
                       Total Novo         
           Additional   Other       Stockholders’   Non   Total 
   Common Stock   Paid-in   Comprehensive   Accumulated   Equity/   controlling   Equity/ 
   Shares   Amount   Capital   Income   Deficit   (Deficit)   Interest   (Deficit) 
Balance, August 31, 2018   207,881,743    207,882    10,053,683    1,139,815    (11,199,989)          201,391    (28,621)   172,770 
                                         
Common stock issued for cash   3,245,444    3,245    3,224,853    -    -    3,228,098    -    3,228,098 
Common stock issued for interest in joint venture   12,000,000    12,000    21,588,000    -    -    21,600,000    -    21,600,000 
Common stock issued for software license   458,349    458    758,109    -    -    758,567    -    758,567 
Fair value of vested stock options   -    -    70,846    -    -    70,846    -    70,846 
Foreign currency translation loss   -    -    -    (37,627)        (37,627)   1,138    (36,489)
Net loss   -    -    -    -    (470,175)   (470,175)   (10,162)   (480,337)
                                         
Balance, May 31, 2019   223,585,536   $223,585   $35,695,491   $1,102,188   $(11,670,164)  $25,351,100   $(37,645)  $25,313,455 
                                         
                                         
Balance, August 31, 2017   201,837,254    201,837    3,381,643         (9,091,977)   (5,508,497)   (20,537)   (5,529,034)
                                         
Common stock issued for cash   25,104    25    15,539    -    -    15,564    -    15,564 
Common stock issued for acquisition   384,110    384    232,771    -    -    233,155    -    233,155 
Common stock issued for conversion of debt   12,452,356    12,453    5,110,446    -    -    5,122,899    -    5,122,899 
Fair value of vested stock options   -    -    1,220,419    -    -    1,220,419    -    1,220,419 
Fair value of modification of stock option terms   -    -    31,536    -    -    31,536    -    31,536 
Foreign currency translation loss   -    -    -    (95,846)        (95,846)   873    (94,973)
Net loss   -    -    -    -    (1,949,743)   (1,949,743)   (6,871)   (1,956,614)
                                         
Balance, May 31, 2018   214,698,824   $214,699   $9,992,354   $(95,846)  $(11,041,720)  $(930,513)  $(26,535)  $(957,048)

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

5
 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended May 31, 2019 and 2018 (unaudited)

 

   Nine Months Ended 
   May 31, 2019   May 31, 2018 
   (unaudited)   (unaudited) 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(480,337)  $(1,956,614)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   71,256    52,287 
Fair value of vested stock options   70,846    1,220,419 
Expense associated with modified stock option terms   -    31,536 
Operating lease expense   98,316    - 
Changes in operating assets and liabilities:          
Accounts receivable   (91,318)   (227,113)
Prepaid expenses and other current assets   7,182    39,503 
Accounts payable   18,628    (343,102)
Accrued expenses   (167,126)   39,552 
Accrued interest   38,076    303,488 
Operating lease liability   (96,498)   - 
Net cash used in operating activities   (530,975)   (840,044)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of furniture and equipment   (103,035)   (83,950)
Payment for acquisition deposit   (377,000)   - 
Amounts loaned for other receivables   (225,924)   (38,929)
Net cash used in investing activities   (705,959)   (122,879)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayments to related parties   (151,257)   (31,580)
Proceeds from the sale of common stock   3,228,098    15,564 
Payments on notes payable   -    (7,056)
Net cash provided by (used in) financing activities   3,076,841    (23,072)
           
Effect of exchange rate changes on cash and cash equivalents   (37,309)   (46,881)
           
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   1,802,598    (1,032,876)
           
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD   675,705    1,896,572 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $2,478,303   $863,696 
           
CASH PAID FOR:          
Interest  $104,443   $170,588 
Income taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Common stock issued for intangible assets  $22,358,567   $- 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

6
 

 

NOVO INTEGRATED SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended May 31, 2019 and 2018 (unaudited)

 

Note 1 - Organization and Basis of Presentation

 

Organization and Line of Business

 

Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.

 

Through Novo Healthnet Limited (“NHL”), our wholly owned Canadian subsidiary, we deliver multi-disciplinary primary healthcare to over 400,000 patients annually through our 15 corporate-owned clinics and a contracted network of 96 affiliate clinics and 229 eldercare centric homes located across Canada. Our team of practitioners and staff are trained for assessment, diagnosis, treatment, pain management, rehabilitation and primary prevention. Our specialized services and products include physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropody, neurological functions, kinesiology, concussion management and baseline testing, women’s pelvic health, sports medicine therapy, assistive devices and private personal training. We do not provide primary care medical services, none of our employees practices primary care medicine, and our services do not require a medical or nursing license.

 

As we continue to build our health science platform of services and products through the integration of technology and rehabilitative science, one component of our lateral business growth strategy includes developing business units centered on the direct control of the grow, extraction, manufacturing and distribution processes for hemp and medical cannabidiol products. Additionally, we continue to expand on our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of a clinic, by extending oversight of patient diagnosis, care and monitoring, directly into the patient’s home, through various mobile telemedicine and diagnostic tools.

 

Since inception and through May 9, 2017, our activities and business operations were limited to raising capital, organizational matters and the implementation of our business plan related to research, development, testing and commercialization of various alternative energy technologies.

 

On April 25, 2017 (the “Effective Date”), the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) the Company; (ii) NHL; (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, the Company agreed to acquire from the NHL Shareholders all of the shares of both common and preferred stock of NHL, held by the NHL Shareholders, in exchange for the issuance by the Company to the NHL Shareholders of shares of the Company’s common stock, such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 167,797,406 restricted shares of Company common stock, representing 85% of the issued and outstanding Company common stock, calculated including all granted and issued options or warrants to acquire the Company common stock as of the Effective Date, but to exclude shares of Company common stock that are subject to a then-current Regulation S offering that was undertaking by the Company (the “Exchange”).

 

On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated Sciences, Inc.

 

The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Exchange was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904.

 

7
 

 

The unaudited consolidated financial statements are prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) were omitted pursuant to such rules and regulations. The results of operations for the nine months ended May 31, 2019 are not necessarily indicative of the results for the year ending August 31, 2019.

 

Basis of Presentation

 

The accompanying consolidated financial statements were prepared in conformity with U.S. GAAP. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD” or “CAD$”); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”).

 

Foreign Currency Translation

 

The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction, with the CAD as the functional currency. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income. The following table details the exchange rates used for the respective periods:

 

   May 31, 2019   May 31, 2018   August 31, 2018 
Period end: CAD to USD exchange rate  $0.7395   $0.7712   $0.7647 
Average period: CAD to USD exchange rate  $0.7540   $0.7901      

 

Note 2 – Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company’s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.

 

8
 

 

Noncontrolling Interest

 

The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

 

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

 

Cash Equivalents

 

For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

 

Accounts Receivable

 

Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $475,329 and $464,527, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

 

  Leasehold improvements 5 years
  Clinical equipment 5 years
  Computer equipment 3 years
  Office equipment 5 years
  Furniture and fixtures 5 years

 

Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at May 31, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.

 

9
 

 

Intangible Assets

 

The Company’s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.

 

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At May 31, 2019, the Company recorded goodwill of $369,750 and $214,455, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.

 

Acquisition Deposits

 

The Company has signed letters of understanding with three potential acquisition candidates which include refundable acquisition deposits totaling $1,445,495 and $1,112,404 at May 31, 2019 and August 31, 2018, respectively.

 

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

 

  Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
     
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
     
  Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

 

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

 

As of May 31, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

 

10
 

 

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;
  identification of performance obligations in the respective contract;
  determination of the transaction price for each performance obligation in the respective contract;
  allocation the transaction price to each performance obligation; and
  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

 

  Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of May 31, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.

 

11
 

 

Foreign Currency Transactions and Comprehensive Income

 

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,102,188 and $1,139,815 at May 31, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

 

Statement of Cash Flows

 

Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

Recent Accounting Pronouncements

 

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU on March 1, 2019 with no material impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 and additional ASUs are now codified as Accounting Standards Codification Standard (“ASC”) 842 - Leases (“ASC 842”). ASC 842 supersedes the lease accounting guidance in ASC 840 Leases and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. It also requires additional disclosures about leasing arrangements. The Company adopted ASC 842 on March 1, 2019 and used the modified retrospective transition approach and did not restate its comparative periods. As of the date of implementation on March 1, 2019, the impact of the adoption of ASC 842 resulted in the recognition of a right of use asset and lease payable obligation on the Company’s consolidated balance sheets of $2,360,787. As the right of use asset and the lease payable obligation were the same upon adoption of ASC 842, there was no cumulative effect impact on the Company’s accumulated deficit.

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.

 

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

 

12
 

 

Note 3 – Related Party Transactions

 

Due to related parties

 

Amounts loaned to the Company by stockholders and officers of the Company are non-interest bearing and payable upon demand. At May 31, 2019 and August 31, 2018, the amount due to related parties was $931,128 and $1,116,261, respectively.

 

On January 31, 2018, a related party converted $813,125 of outstanding principal and accrued interest into 1,976,483 shares of the Company’s common stock. The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

 

Note 4 – Accounts Receivables, net

 

Accounts receivables, net at May 31, 2019 and August 31, 2018 consisted of the following:

 

   May 31,   August 31, 
   2019   2018 
Trade receivables  $1,571,743   $1,564,180 
Amounts earned but not billed   286,615    237,892 
    1,858,358    1,802,072 
Allowance for doubtful accounts   (475,329)   (464,527)
Accounts receivable, net  $1,383,029   $1,337,545 

 

Note 5 – Other Receivables

 

Other receivables at May 31, 2019 and August 31, 2018 consisted of the following:

 

   May 31,   August 31, 
   2019   2018 
Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019 (currently in default)  $277,312   $286,763 
Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020   29,580    30,588 
Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019   73,950    76,470 
Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022   55,463    57,352 
Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020   225,924    - 
Total other receivables   662,229    451,173 
Current portion   (577,186)   (393,821)
Long-term portion  $85,043   $57,352 

 

13
 

 

Note 6 – Property and Equipment

 

Property and equipment at May 31, 2019 and August 31, 2018 consisted of the following:

 

   May 31,   August 31, 
   2019   2018 
Leasehold Improvements  $444,449   $372,010 
Clinical equipment   274,395    269,741 
Computer equipment   21,890    22,636 
Office equipment   26,658    24,658 
Furniture and fixtures   38,315    39,620 
    805,707    728,665 
Accumulated depreciation   (387,410)   (328,344)
Total  $418,297   $400,321 

 

Depreciation expense for the nine months ended May 31, 2019 and 2018 was $71,256 and $52,287, respectively.

 

Note 7 – Intangible Assets

 

Intangible assets at May 31, 2019 and August 31, 2018 consisted of the following:

 

   May 31, 2019   August 31, 2018 
Land use rights  $21,600,000   $- 
Software license   758,567    - 
    22,358,567    - 
Accumulated amortization   -    - 
Total  $22,358,567   $- 

 

There was no amortization expense during the nine months ended May 31, 2019 and 2018 as the listed intangible assets have not been placed in service.

 

Note 8 – Accrued Expenses

 

Accrued expenses at May 31, 2019 and August 31, 2018 consisted of the following:

 

   May 31,   August 31, 
   2019   2018 
Accrued liabilities  $57,856   $266,123 
Accrued payroll   119,291    106,761 
Other   30,861    11,114 
   $208,008   $383,998 

 

14
 

 

Note 9 – Notes Payable

 

Notes payable at May 31, 2019 and August 31, 2018 consisted of the following:

 

   May 31, 2019   August 31, 2018 
Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019. Currently in Dispute.  $369,750   $382,350 
    369,750    382,350 
Current portion   (369,750)   (382,350)
Long-term portion  $-   $- 

 

Note 10 – Debentures, related parties

 

On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 ($4,968,990 at November 30, 2017) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019.

 

On January 31, 2018, the debenture holders converted 75% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 10,475,872 shares of the Company’s common stock. The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. At May 31, 2019, the amount of debentures outstanding was $1,183,664.

 

Note 11 – Leases

 

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate.

 

The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. Effective March 1, 2019, the Company adopted the provision of ASC 842 Leases.

 

The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of May 31, 2019:

 

   Classification on Balance Sheet  May 31, 2019 
Assets       
Operating lease assets  Operating lease right of use assets  $2,201,893 
Total lease assets     $2,201,893 
         
Liabilities        
Current liabilities        
Operating lease liability  Current operating lease liability  $413,896 
Noncurrent liabilities        
Operating lease liability  Long-term operating lease liability   1,789,779 
Total lease liability     $2,203,675 

 

15
 

 

Lease obligations at May 31, 2019 consisted of the following:

 

Twelve months ending May 31,    
2020  $575,245 
2021   573,476 
2022   464,407 
2023   401,394 
2024   197,454 
2025   149,001 
Thereafter   412,330 
Total payments   2,773,307 
Amount representing interest   (569,632)
Lease obligation, net   2,203,675 
Less lease obligation, current portion   (413,896)
Lease obligation, long-term portion  $1,789,779 

 

The lease expense for the three months ended May 31, 2019 (since adoption of ASC 842) was $142,676, which consisted of amortization expense of $98,316 and interest expense of $44,360. The cash paid under operating leases during the three months ended May 31, 2019 was $115,311. At May 31, 2019, the weighted average remaining lease terms were 6.0 years and the weighted average discount rate was 8%

 

Note 12 – Stockholders’ Deficit

 

Convertible preferred stock

 

The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. At May 31, 2019 and August 31, 2018 there were 0 and 0 convertible preferred shares issued, outstanding and designated, respectively.

 

Common stock

 

The Company has authorized 499,000,000 shares of $0.001 par value common stock. At May 31, 2019 and August 31, 2018 there were 223,585,536 and 207,881,743 common shares issued and outstanding, respectively.

 

During the nine months ended May 31, 2019, the Company issued:

 

  3,245,444 restricted shares of common stock for cash proceeds of $3,228,098;
     
  12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate; and
     
  458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567.

 

Stock options/warrants

 

On September 8, 2015, the Company adopted the 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 5,000,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. As of May 31, 2019, 4,987,500 shares were available under the 2015 Plan for future grants, awards, options or share issuances. However, because the shares issuable under the 2015 Plan or issuable upon conversion of awards granted under the 2015 Plan are no longer registered under the Securities Exchange Act of 1934, as amended, the Company does not intend to issue any additional grants under the 2015 Plan.

 

On January 16, 2018, the Company adopted the Novo Integrated Sciences, Inc. 2018 Incentive Plan (the “2018 Plan”). Under the 2018 Plan, 10,000,000 shares of common stock are authorized for issuance to employees, non-employees, directors and key consultants to the Company or its subsidiaries. The 2018 Plan authorizes equity-based and cash-based incentives for participants. There were 9,875,000 shares available for award at May 31, 2019 under the 2018 Plan.

 

16
 

  

The following is a summary of stock option/warrant activity:

 

           Weighted     
       Weighted   Average     
   Options/   Average   Remaining   Aggregate 
   Warrants   Exercise   Contractual   Intrinsic 
   Outstanding   Price   Life   Value 
Outstanding, August 31, 2018   10,030,000    0.30    4.56   $7,045,500 
Granted   75,000    0.95           
Forfeited   (10,000)   2.00           
Exercised   -                
Outstanding, May 31, 2019   10,095,000    0.30    3.83   $9,573,000 
Exercisable, May 31, 2019   10,095,000   $0.30    3.83   $9,573,000 

 

The exercise price for options/warrants outstanding at May 31, 2019:

 

Outstanding and Exercisable 
Number of    Exercise 
Options/Warrants   Price 
 5,500,000   $0.16 
 1,000,000    0.32 
 50,000    0.33 
 120,000    0.40 
 2,000,000    0.42 
 100,000    0.50 
 1,000,000    0.62 
 250,000    0.80 
 75,000    0.95 
 10,095,000      

 

For options granted during the fiscal year ending August 31, 2019 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.94 and the weighted-average exercise price of such options/warrants was $0.95. No options were granted during the fiscal year ending August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

 

For options granted during the fiscal year ended August 31, 2018 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.39 and the weighted-average exercise price of such options/warrants was $0.40. No options were granted during the fiscal year ended August 31, 2018 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

 

The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $70,846 and $1,220,419 during the nine months ended May 31, 2019 and 2018, respectively. At May 31, 2019, the unamortized stock option expense was $0.

  

The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through May 31, 2019, are as follows:

 

Risk-free interest rate   2.78%
Expected life of the options   3.5 years 
Expected volatility   294%
Expected dividend yield   0%

 

Note 13 – Commitments and Contingencies

 

Litigation

 

The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position as of May 31, 2019, results of operations, cash flows or liquidity of the Company.

 

Note 14 – Subsequent Events

 

On June 4, 2019, the Company sold 21,413 restricted shares of common stock to an accredited investor for a purchase price of $22,269.

 

17
 

  

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), provide a safe harbor for forward-looking statements made by or on behalf of the Company. The Company and its representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission (“SEC”) and in our reports and presentations to stockholders or potential stockholders. In some cases forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in the Part I, Item 1A, “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2018.

 

Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this report are made on the basis of management’s assumptions and analysis, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances.

 

Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this report to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

 

Overview of the Company

 

Through Novo Healthnet Limited (“NHL”), our wholly owned Canadian subsidiary, we deliver multi-disciplinary primary healthcare to over 400,000 patients annually through our 15 corporate-owned clinics and a contracted network of 96 affiliate clinics and 229 eldercare centric homes located across Canada. Our team of practitioners and staff are trained for assessment, diagnosis, treatment, pain management, rehabilitation and primary prevention. Our specialized services and products include physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropody, neurological functions, kinesiology, concussion management and baseline testing, women’s pelvic health, sports medicine therapy, assistive devices and private personal training. We do not provide primary care medical services, none of our employees practices primary care medicine, and our services do not require a medical or nursing license.

 

As we continue to build our health science platform of services and products through the integration of technology and rehabilitative science, one component of our lateral business growth strategy includes developing business units centered on the direct control of the grow, extraction, manufacturing and distribution processes for hemp and medical cannabidiol products. Additionally, we continue to expand on our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of a clinic, by extending oversight of patient diagnosis, care and monitoring, directly into the patient’s home, through various mobile telemedicine and diagnostic tools.

 

Our strict adherence to public regulatory standards, as well as self-imposed standards of excellence, have allowed us to navigate with ease through the industry’s licensing and regulatory framework. Compliant treatment, data and administrative protocols are managed through a team of highly trained, certified healthcare and administrative professionals. We and our affiliates provide service to the Canadian property and casualty insurance industry, resulting in a regulated framework governed by the Financial Services Commission of Ontario. All of our services and those of our affiliates are regulated by the various professional associations related to the clinical professionals contracted or employed by us. In 2013, NHL received its accreditation from the Commission on Accreditation of Rehabilitation Facilities (“CARF”). Currently, NHL is undergoing the CARF re-accreditation process.

 

When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated Sciences, Inc. and its consolidated subsidiaries.

 

For the three months ended May 31, 2019 compared to the three months ended May 31, 2018

 

Revenues for the three months ended May 31, 2019 were $2,489,575, representing an increase of $166,406, or 7.2%, from $2,323,169 for the same period in 2018. The increase in revenue is due to the opening of a new clinic in September 2018 and the relocation of certain clinics, during the summer of 2018, allowing the Company to sell additional services to customers as a result of more spacious facilities.

 

Cost of revenues for the three months ended May 31, 2019 were $1,556,865, representing an increase of $138,866, or 9.8%, from $1,417,999 for the same period in 2018. The increase in cost of revenues is principally due the increase in revenue. Cost of revenues as a percentage of revenue was 62.5% for the three months ended May 31, 2019 and 61.0% for same period in 2018. The increase in cost of revenues as a percentage of revenue is principally due to higher costs.

 

Operating costs for the three months ended May 31, 2019 were $995,838, representing a decrease of $86,169, or 8.0%, from $1,082,007 for the same period in 2018. The decrease in operating costs is principally attributed to a decrease in stock-based compensation of $111,003.

 

Interest expense for the three months ended May 31, 2019 was $41,735 representing a decrease of $961, or 2.3%, from $42,696 for the same period in 2018. The decrease is not significant.

 

Net loss for the three months ended May 31, 2019 was $100,773, representing a decrease of $118,640, or 54.1%, from $219,413 for the same period in 2018. The decrease in net loss is due to the reasons described above.

 

18
 

 

For the nine months ended May 31, 2019 compared to the nine months ended May 31, 2018

 

Revenues for the nine months ended May 31, 2019 were $7,001,607, representing an increase of $278,782, or 4.1%, from $6,722,825 for the same period in 2018. The increase in revenue is due to us being able to sell additional services to customers as a result of the acquisition of Executive Fitness Leaders in December 2017, the opening of a new clinic in September 2018, and the relocation of certain clinics during the summer of 2018 to more spacious facilities.

 

Cost of revenues for the nine months ended May 31, 2019 were $4,305,688, representing an increase of $172,400, or 4.2%, from $4,133,288 for the same period in 2018. The increase in cost of revenues is principally due to the increase in revenue. Cost of revenues as a percentage of revenue was 61.5% for the nine months ended May 31, 2019 and 61.5% for same period in 2018. There was no change in cost of revenues as a percentage of revenue.

 

Operating costs for the nine months ended May 31, 2019 were $3,053,086, representing a decrease of $1,012,415, or 24.9%, from $4,065,501 for the same period in 2018. The decrease in operating costs is attributed to a decrease in stock-based compensation of $1,149,573 offset by an increase in payroll and rental fees.

 

Interest expense for the nine months ended May 31, 2019 was $136,643, representing a decrease of $344,338, or 71.6%, from $480,981 for the same period in 2018. The decrease is due to less debt outstanding as a result of approximately $5.1 million of related party debt being converted to common stock in January 2018.

 

Net loss for the nine months ended May 31, 2019 was $480,337, representing a decrease of $1,476,277, or 75.5%, from $1,956,614 for the same period in 2018. The decrease in net loss is due to the reasons described above.

 

Liquidity and Capital Resources

 

As shown in the accompanying financial statements, for the nine months ended May 31, 2019, the Company had a net loss of $480,337.

 

During the nine months ended May 31, 2019, the Company used cash in operating activities of $530,975 compared to $840,044 for the same period in 2018. The principal reason for the decrease is the decrease in net loss incurred during the nine months ended May 31, 2019 as compared to the same period in 2018, changes in non-cash expense of stock-based compensation and changes in working capital accounts during the nine months ended May 31, 2019 compared to the same period in 2018.

 

During the nine months ended May 31, 2019, the Company used cash in investing activities of $705,959 compared to $122,879 for the same period in 2018. The principal reason for the change is a deposit paid for a potential acquisition and the increase of amounts loaned for other receivables during the nine months ended May 31, 2019 compared to the same period in 2018.

 

During the nine months ended May 31, 2019, the Company generated cash of $3,076,841 from financing activities compared to cash used in financing activities of $23,072 for the same period in 2018. The principal reason for the change is the sale of shares of common stock for $3,228,098 during the nine months ended May 31, 2019, offset by an increase of repayments of amounts due to related parties. During the nine months ended May 31, 2018 there were only $15,564 of sales of shares of common stock.

 

On November 16, 2018, the Company accepted a $30,000 subscription agreement from an accredited investor residing outside the United States for the sale of 17,647 shares of restricted common stock, resulting in an effective price per share of $1.70. The shares were issued on November 20, 2018.

 

On November 16, 2018, the Company accepted a $501,929 subscription agreement from an accredited investor residing outside the United States for the sale of 545,575 shares of restricted common stock, resulting in an effective price per share of $0.92. The shares were issued on November 20, 2018.

 

On December 18, 2018, the Company accepted a $1,867,250 subscription agreement from an accredited investor residing outside the United States for the sale of 2,029,620 shares of restricted common stock, resulting in an effective price per share of $0.92. The shares were issued on December 20, 2018.

 

19
 

 

On January 15, 2019, the Company accepted a $180,744 subscription agreement from an accredited investor residing outside the United States for the sale of 115,271 shares of restricted common stock, resulting in an effective price per share of $1.57. The shares were issued on January 18, 2019.

 

On April 3, 2019, the Company accepted a $149,740 subscription agreement from an accredited investor residing outside the United States for the sale of 116,078 shares of restricted common stock, resulting in an effective price per share of $1.29. The shares were issued on April 5, 2019.

 

On April 19, 2019, the Company accepted a $112,140 subscription agreement from an accredited investor residing outside the United States for the sale of 89,712 shares of restricted common stock, resulting in an effective price per share of $1.25. The shares were issued on April 24, 2019.

 

On April 30, 2019, the Company accepted a $200,000 subscription agreement from an accredited investor residing outside the United States for the sale of 170,941 shares of restricted common stock, resulting in an effective price per share of $1.17. The shares were issued on May 7, 2019.

 

On May 1, 2019, the Company accepted a $37,235 subscription agreement from an accredited investor residing outside the United States for the sale of 32,100 shares of restricted common stock, resulting in an effective price per share of $1.16. The shares were issued on May 3, 2019.

 

On May 3, 2019, the Company accepted a $149,060 subscription agreement from an accredited investor residing outside the United States for the sale of 128,500 shares of restricted common stock, resulting in an effective price per share of $1.16. The shares were issued on May 3, 2019.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

We believe that the following critical policies affect our more significant judgments and estimates used in preparation of our financial statements.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

20
 

 

Noncontrolling Interest

 

The Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

 

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

 

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;
     
  identification of performance obligations in the respective contract;
     
  determination of the transaction price for each performance obligation in the respective contract;
     
  allocation of the transaction price to each performance obligation; and
     
  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

 

  Healthcare services - gross service revenue is recorded in the accounting records at the time the services are provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

 

21
 

 

Foreign Currency Transactions and Comprehensive Income

 

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar. Translation gains (losses) are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

 

New Accounting Pronouncements

 

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU on March 1, 2019 with no material impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 and additional ASUs are now codified as Accounting Standards Codification Standard (“ASC”) 842 - Leases (“ASC 842”). ASC 842 supersedes the lease accounting guidance in ASC 840 Leases, and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. It also requires additional disclosures about leasing arrangements. The Company adopted ASC 842 on March 1, 2019 and used the modified retrospective transition approach and did not restate its comparative periods. As of the date of implementation on March 1, 2019, the impact of the adoption of ASC 842 resulted in the recognition of a right of use asset and lease payable obligation on the Company’s consolidated balance sheets of $2,360,787. As the right of use asset and the lease payable obligation were the same upon adoption of ASC 842, there was no cumulative effect impact on the Company’s accumulated deficit.

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.

 

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

 

Recent accounting pronouncements issued by the FASB, the American Institute of Certified Public Accountants and the SEC did not or are not believed by management to have a material effect on the Company’s financial statements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

22
 

 

ITEM 4. CONTROLS AND PROCEDURES

 

The Company’s Chief Executive Officer and Principal Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of May 31, 2019. Based upon such evaluation, the Chief Executive Officer and Principal Financial Officer have concluded that, as of May 31, 2019, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the fiscal quarter ended May 31, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Except as set forth herein, as of the date of this Quarterly Report on Form 10-Q, there are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or which our property is the subject. In addition, none of our officers, directors, affiliates or 5% stockholders (or any associates thereof) is a party adverse to us, or has a material interest adverse to us, in any material proceeding.

 

ITEM 1A. RISK FACTORS

 

Not required for smaller reporting companies.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On April 3, 2019, the Company sold 116,078 restricted shares of common stock to an accredited investor for a purchase price of $149,740. The shares were issued on April 5, 2019.

 

On April 19, 2019, the Company sold 89,712 restricted shares of common stock to an accredited investor for a purchase price of $112,140. The shares were issued on April 24, 2019.

 

On April 30, 2019, the Company sold 170,941 restricted shares of common stock to an accredited investor for a purchase price of $200,000. The shares were issued on May 7, 2019.

 

On May 1, 2019, the Company sold 32,100 restricted shares of common stock to an accredited investor for a purchase price of $37,235. The shares were issued on May 3, 2019.

 

On May 3, 2019, the Company sold 128,500 restricted shares of common stock to an accredited investor for a purchase price of $149,060. The shares were issued on May 3, 2019.

 

The above sales were made pursuant to an exemption from registration as set forth in Regulation S under the Securities Act. The issuances involved an offer and sale of securities outside the United States. The offers and sales were made in offshore transactions and no directed selling efforts were made by the issuer, a distributor, their affiliates or any persons acting on their behalf.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

There have been no defaults in any material payments during the covered period.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

23
 

 

ITEM 5. OTHER INFORMATION

 

(a) None.

 

(b) There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors since the Company last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.

 

ITEM 6. EXHIBITS

 

Exhibit
Number
  Description of Document
     
31.1   Rule 13a-14(a) Certification of Principal Executive Officer.
     
31.2   Rule 13a-14(a) Certification of Principal Financial Officer.
     
32.1   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer.
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase
     
101.LAB   XBRL Taxonomy Extension Labels Linkbase
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase

 

24
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereto duly authorized:

 

  NOVO INTEGRATED SCIENCES, INC.
     
Dated: July 11, 2019 By: /s/ Robert Mattacchione
    Robert Mattacchione
   

Chief Executive Officer

(principal executive officer)

     
  By: /s/ Klara Radulyne
    Klara Radulyne
   

Principal Financial Officer

(principal financial officer and principal accounting officer)

 

25
 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATIONS

 

I, Robert Mattacchione, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended May 31, 2019 of Novo Integrated Sciences, Inc.; and
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; and
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; and
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: July 11, 2019 By: /s/ Robert Mattacchione
    Robert Mattacchione
    Chief Executive Officer (principal executive officer)

 

   

 

 

EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATIONS

 

I, Klara Radulyne, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended May 31, 2019 of Novo Integrated Sciences, Inc.; and
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; and
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; and
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: July 11, 2019 By: /s/ Klara Radulyne
    Klara Radulyne
    Principal Financial Officer

 

   

 

 

EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Novo Integrated Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended May 31, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Robert Mattacchione, Chief Executive Officer of the Company, and I, Klara Radulyne, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: July 11, 2019 /s/ Robert Mattacchione
 

Robert Mattacchione, Chief Executive Officer

(principal executive officer)

   
  /s/ Klara Radulyne
 

Klara Radulyne, Principal Financial Officer

(principal financial officer)

 

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

   

 

EX-101.INS 5 nvos-20190531.xml XBRL INSTANCE FILE 0001138978 2018-09-01 2019-05-31 0001138978 2019-07-05 0001138978 2017-08-31 0001138978 2018-08-31 0001138978 NVOS:TurbineTruckEnginesIncMember 2018-09-01 2019-05-31 0001138978 NVOS:ShareExchangeAgreementMember NVOS:NHLMember 2017-04-23 2017-04-25 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2019-05-31 0001138978 NVOS:AdvanceToCorporationOneMember 2019-05-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2019-05-31 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2018-09-01 2019-05-31 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2017-09-01 2018-08-31 0001138978 us-gaap:LeaseholdImprovementsMember 2018-08-31 0001138978 NVOS:ClinicalEquipmentMember 2018-08-31 0001138978 us-gaap:ComputerEquipmentMember 2018-08-31 0001138978 us-gaap:OfficeEquipmentMember 2018-08-31 0001138978 us-gaap:FurnitureAndFixturesMember 2018-08-31 0001138978 NVOS:NotesPayableMember 2018-08-31 0001138978 NVOS:NotesPayableMember 2018-09-01 2019-05-31 0001138978 NVOS:ExercisePriceRangeOneMember 2019-05-31 0001138978 NVOS:ExercisePriceRangeTwoMember 2019-05-31 0001138978 NVOS:ExercisePriceRangeThreeMember 2019-05-31 0001138978 NVOS:ExercisePriceRangeFourMember 2019-05-31 0001138978 NVOS:ExercisePriceRangeFiveMember 2019-05-31 0001138978 NVOS:NotesPayableMember 2017-09-01 2018-08-31 0001138978 NVOS:FiveDebenturesMember 2013-09-30 0001138978 NVOS:FiveDebenturesMember NVOS:CADMember 2013-09-30 0001138978 NVOS:FiveDebenturesMember 2017-11-29 2017-12-02 0001138978 NVOS:TwoThousandAndFifteenIncentiveCompensationPlanMember srt:MaximumMember 2015-09-07 2015-09-08 0001138978 NVOS:ExercisePriceRangeSixMember 2019-05-31 0001138978 NVOS:PeriodEndMember NVOS:CADMember 2018-08-31 0001138978 NVOS:AveragePeriodMember NVOS:CADMember 2018-08-31 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationOneMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2018-08-31 0001138978 NVOS:ExercisePriceRangeSevenMember 2019-05-31 0001138978 2018-01-29 2018-01-31 0001138978 2018-01-31 0001138978 NVOS:FiveDebenturesMember 2013-09-29 2013-09-30 0001138978 NVOS:TwoThousandAndEighteenIncentivePlanMember 2018-01-15 2018-01-16 0001138978 NVOS:ExercisePriceRangeEightMember 2019-05-31 0001138978 NVOS:ExercisePriceRangeNineMember 2019-05-31 0001138978 NVOS:DebenturesMember 2018-01-29 2018-01-31 0001138978 NVOS:DebenturesMember 2018-01-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2019-05-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2017-09-01 2018-08-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2018-09-01 2019-05-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2017-09-01 2018-08-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2018-09-01 2019-05-31 0001138978 2019-05-31 0001138978 2017-09-01 2018-05-31 0001138978 NVOS:PeriodEndMember NVOS:CADMember 2019-05-31 0001138978 NVOS:PeriodEndMember NVOS:CADMember 2018-05-31 0001138978 NVOS:AveragePeriodMember NVOS:CADMember 2019-05-31 0001138978 NVOS:AveragePeriodMember NVOS:CADMember 2018-05-31 0001138978 NVOS:AdvanceToCorporationOneMember 2017-09-01 2018-08-31 0001138978 NVOS:AdvanceToCorporationOneMember 2018-09-01 2019-05-31 0001138978 NVOS:NotesPayableMember 2019-05-31 0001138978 2017-09-01 2018-08-31 0001138978 NVOS:AugustThirtyOneTwoThousandAndNineteenMember 2018-09-01 2019-05-31 0001138978 NVOS:NovoHealthnetKemptvilleCentreIncMember 2019-05-31 0001138978 us-gaap:LeaseholdImprovementsMember 2018-09-01 2019-05-31 0001138978 NVOS:ClinicalEquipmentMember 2018-09-01 2019-05-31 0001138978 us-gaap:ComputerEquipmentMember 2018-09-01 2019-05-31 0001138978 us-gaap:OfficeEquipmentMember 2018-09-01 2019-05-31 0001138978 us-gaap:FurnitureAndFixturesMember 2018-09-01 2019-05-31 0001138978 us-gaap:LeaseholdImprovementsMember 2019-05-31 0001138978 NVOS:ClinicalEquipmentMember 2019-05-31 0001138978 us-gaap:ComputerEquipmentMember 2019-05-31 0001138978 us-gaap:OfficeEquipmentMember 2019-05-31 0001138978 us-gaap:FurnitureAndFixturesMember 2019-05-31 0001138978 NVOS:ApkaHealthIncMember 2019-05-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2019-05-31 0001138978 2019-03-01 2019-05-31 0001138978 2018-03-01 2018-05-31 0001138978 2018-05-31 0001138978 NVOS:SoftwareLicenseMember 2018-09-01 2019-05-31 0001138978 NVOS:LandUseRightsMember 2018-09-01 2019-05-31 0001138978 NVOS:AdvanceToCorporationFourMember 2019-05-31 0001138978 NVOS:AdvanceToCorporationFourMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationFourMember 2018-09-01 2019-05-31 0001138978 NVOS:LandUseRightsMember 2019-05-31 0001138978 NVOS:LandUseRightsMember 2018-08-31 0001138978 NVOS:SoftwareLicenseMember 2019-05-31 0001138978 NVOS:SoftwareLicenseMember 2018-08-31 0001138978 NVOS:JointVentureAgreementMember 2018-09-01 2019-05-31 0001138978 NVOS:JointVentureAgreementMember 2019-05-31 0001138978 NVOS:LicensingAgreementMember 2018-09-01 2019-05-31 0001138978 NVOS:LicensingAgreementMember 2019-05-31 0001138978 us-gaap:CommonStockMember 2018-09-01 2019-05-31 0001138978 us-gaap:CommonStockMember 2017-09-01 2018-05-31 0001138978 us-gaap:CommonStockMember 2018-08-31 0001138978 us-gaap:CommonStockMember 2019-05-31 0001138978 us-gaap:CommonStockMember 2017-08-31 0001138978 us-gaap:CommonStockMember 2018-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2018-09-01 2019-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2017-09-01 2018-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2018-08-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2019-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2017-08-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-01 2019-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-01 2018-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-08-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-08-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2018-09-01 2019-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2017-09-01 2018-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2018-08-31 0001138978 us-gaap:NoncontrollingInterestMember 2019-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2017-08-31 0001138978 us-gaap:NoncontrollingInterestMember 2018-05-31 0001138978 us-gaap:RetainedEarningsMember 2018-09-01 2019-05-31 0001138978 us-gaap:RetainedEarningsMember 2017-09-01 2018-05-31 0001138978 us-gaap:RetainedEarningsMember 2018-08-31 0001138978 us-gaap:RetainedEarningsMember 2019-05-31 0001138978 us-gaap:RetainedEarningsMember 2017-08-31 0001138978 us-gaap:RetainedEarningsMember 2018-05-31 0001138978 NVOS:TotalNovoStockholdersDeficitMember 2018-09-01 2019-05-31 0001138978 NVOS:TotalNovoStockholdersDeficitMember 2017-09-01 2018-05-31 0001138978 NVOS:TotalNovoStockholdersDeficitMember 2018-08-31 0001138978 NVOS:TotalNovoStockholdersDeficitMember 2019-05-31 0001138978 NVOS:TotalNovoStockholdersDeficitMember 2017-08-31 0001138978 NVOS:TotalNovoStockholdersDeficitMember 2018-05-31 0001138978 us-gaap:AccountingStandardsUpdate201602Member 2019-05-31 0001138978 us-gaap:AccountingStandardsUpdate201602Member 2019-03-01 2019-05-31 0001138978 NVOS:FiveDebenturesMember 2017-11-30 0001138978 us-gaap:SubsequentEventMember NVOS:AccreditedInvestorMember 2019-06-03 2019-06-04 0001138978 NVOS:TwoThousandAndEighteenIncentivePlanMember 2019-05-31 0001138978 NVOS:TwoThousandAndFifteenIncentiveCompensationPlanMember 2019-05-30 0001138978 srt:ParentCompanyMember 2018-09-01 2019-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CAD Novo Integrated Sciences, Inc. 0001138978 10-Q 2019-05-31 false --08-31 Non-accelerated Filer Q3 223606949 675705 2478303 1337545 1383029 161838 149718 400321 418297 4743099 31681736 1307599 1283735 156121 414965 188321 1116261 931128 382350 369750 4570329 6368281 207882 223585 10053683 35695491 1139815 1102188 -11199989 -11670164 4743099 31681736 4305688 4133288 1556865 1417999 2695919 2589537 932710 905170 33085 86640 3846 17900 3053086 4065501 995838 1082007 -357167 -1475964 -63128 -176837 -123170 -480650 -37645 -42576 -480337 -1956614 -100773 -219413 -10162 -6871 -1515 -1515 -470175 -1949743 -99258 -217898 -517964 -2052460 -164380 -227918 -0.00 -0.01 -0.00 -0.00 215193998 207568978 223258368 214684089 0.001 0.001 1000000 1000000 0 0 0 0 0.001 0.001 499000000 499000000 207881743 223585536 207881743 223585536 71256 52287 18628 -343102 -167126 39552 38076 303488 91318 227113 103035 83950 7056 -28621 -37645 -5529034 172770 25313455 -957048 207882 223585 201837 214699 10053683 35695491 3381643 9992354 1139815 1102188 -95846 -28621 -37645 -20537 -26535 -11199989 -11670164 -9091977 -11041720 201391 25351100 -5508497 -930513 201391 25351100 3020001 3978861 991992 1064107 -480337 -1956614 -100773 -219413 -10162 -6871 -470175 -1949743 -470175 -1949743 233155 384 232771 233155 6904 2019 1224000 6402512 3894809 4968990 604113 584205 369750 214455 104443 170588 1112404 1445495 2568909 4588236 3346329 4578502 -37627 -95846 -63607 -8505 3228098 15564 -7182 -39503 151257 31580 -530975 -840044 -705959 -122879 3076841 -23072 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 - Organization and Basis of Presentation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Organization and Line of Business</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Novo Integrated Sciences, Inc. (&#8220;Novo Integrated&#8221;) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company&#8217;s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Novo Integrated and its consolidated subsidiaries.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Through Novo Healthnet Limited (&#8220;NHL&#8221;), our wholly owned Canadian subsidiary, we deliver multi-disciplinary primary healthcare to over 400,000 patients annually through our 15 corporate-owned clinics and a contracted network of 96 affiliate clinics and 229 eldercare centric homes located across Canada. Our team of practitioners and staff are trained for assessment, diagnosis, treatment, pain management, rehabilitation and primary prevention. Our specialized services and products include physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropody, neurological functions, kinesiology, concussion management and baseline testing, women&#8217;s pelvic health, sports medicine therapy, assistive devices and private personal training. We do not provide primary care medical services, none of our employees practices primary care medicine, and our services do not require a medical or nursing license.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As we continue to build our health science platform of services and products through the integration of technology and rehabilitative science, one component of our lateral business growth strategy includes developing business units centered on the direct control of the grow, extraction, manufacturing and distribution processes for hemp and medical cannabidiol products. Additionally, we continue to expand on our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of a clinic, by extending oversight of patient diagnosis, care and monitoring, directly into the patient&#8217;s home, through various mobile telemedicine and diagnostic tools.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception and through May 9, 2017, our activities and business operations were limited to raising capital, organizational matters and the implementation of our business plan related to research, development, testing and commercialization of various alternative energy technologies.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 25, 2017 (the &#8220;Effective Date&#8221;), the Company entered into a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) by and between (i) the Company; (ii) NHL; (iii) ALMC-ASAP Holdings Inc. (&#8220;ALMC&#8221;); (iv) Michael Gaynor Family Trust (the &#8220;MGFT&#8221;); (v) 1218814 Ontario Inc. (&#8220;1218814&#8221;); and (vi) Michael Gaynor Physiotherapy Professional Corp. (&#8220;MGPP,&#8221; and together with ALMC, MGFT and 1218814, the &#8220;NHL Shareholders&#8221;). Pursuant to the terms of the Share Exchange Agreement, the Company agreed to acquire from the NHL Shareholders all of the shares of both common and preferred stock of NHL, held by the NHL Shareholders, in exchange for the issuance by the Company to the NHL Shareholders of shares of the Company&#8217;s common stock, such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 167,797,406 restricted shares of Company common stock, representing 85% of the issued and outstanding Company common stock, calculated including all granted and issued options or warrants to acquire the Company common stock as of the Effective Date, but to exclude shares of Company common stock that are subject to a then-current Regulation S offering that was undertaking by the Company (the &#8220;Exchange&#8221;).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated Sciences, Inc.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Exchange was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited consolidated financial statements are prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company&#8217;s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) were omitted pursuant to such rules and regulations. The results of operations for the nine months ended May 31, 2019 are not necessarily indicative of the results for the year ending August 31, 2019.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of Presentation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements were prepared in conformity with U.S. GAAP. The Company&#8217;s Canadian subsidiaries&#8217; functional currency is the Canadian Dollar (&#8220;CAD&#8221; or &#8220;CAD$&#8221;); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (&#8220;$&#8221; or &#8220;USD&#8221;).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Foreign Currency Translation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounts of the Company&#8217;s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 830,&#160;<i>Foreign Currency Transaction</i>, with the CAD as the functional currency. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&#8217; equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220,&#160;<i>Comprehensive Income</i>. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income. The following table details the exchange rates used for the respective periods:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31, 2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Period end: CAD to USD exchange rate</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7395</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7712</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7647</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average period: CAD to USD exchange rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7540</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7901</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; Summary of Significant Accounting Policies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Principles of Consolidation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company&#8217;s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Noncontrolling Interest</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB ASC Topic 810,&#160;<i>Consolidation,</i>&#160;which governs the accounting for and reporting of non-controlling interests (&#8220;NCIs&#8221;) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent&#8217;s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cash Equivalents</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Accounts Receivable</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $475,329 and $464,527, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Property and Equipment</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; line-height: 107%">&#160;</td> <td style="width: 48%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3 years</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Office equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Long-Lived Assets</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the provisions of ASC Topic 360,&#160;<i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at May 31, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Intangible Assets</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Goodwill</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At May 31, 2019, the Company recorded goodwill of $369,750 and $214,455, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Acquisition Deposits</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has signed letters of understanding with three potential acquisition candidates which include refundable acquisition deposits totaling $1,445,495 and $1,112,404 at May 31, 2019 and August 31, 2018, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For certain of the Company&#8217;s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB ASC Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825,&#160;<i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%">&#160;</td> <td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480,&#160;<i>Distinguishing Liabilities from Equity</i>, and FASB ASC Topic 815,&#160;<i>Derivatives and Hedging</i>.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 31, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue Recognition</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09,&#160;<i>Revenue from Contracts with Customers</i>&#160;(&#8220;Topic 606&#8221;), became effective for the Company on March 1, 2018. The Company&#8217;s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the &#8220;modified retrospective&#8221; transition method for open contracts for the implementation of Topic 606<i>.</i>&#160;As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company&#8217;s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605,&#160;<i>Revenue Recognition</i>.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">executed contracts with the Company&#8217;s customers that it believes are legally enforceable;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">identification of performance obligations in the respective contract;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">determination of the transaction price for each performance obligation in the respective contract;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">allocation the transaction price to each performance obligation; and</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">recognition of revenue only when the Company satisfies each performance obligation.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These five elements, as applied to healthcare services, the Company&#8217;s sole revenue category, is summarized below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 107%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider&#8217;s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income Taxes</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i>Income Taxes</i>. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock-Based Compensation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company records stock-based compensation in accordance with FASB ASC Topic 718,&#160;<i>Compensation &#8211; Stock Compensation</i>. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basic and Diluted Earnings Per Share</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings per share is calculated in accordance with ASC Topic 260,&#160;<i>Earnings Per Share</i>. Basic earnings per share (&#8220;EPS&#8221;) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of May 31, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Foreign Currency Transactions and Comprehensive Income</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company&#8217;s Canadian subsidiaries is the CAD. Translation gains of $1,102,188 and $1,139,815 at May 31, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders&#8217; equity section of the balance sheet.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Statement of Cash Flows</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flows from the Company&#8217;s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2016, the FASB issued ASU 2016-16,&#160;<i>Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory</i>, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU on March 1, 2019 with no material impact on the Company&#8217;s financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>&#160;. ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 and additional ASUs are now codified as Accounting Standards Codification Standard (&#8220;ASC&#8221;) 842 -&#160;<i>Leases</i>&#160;(&#8220;ASC 842&#8221;). ASC 842 supersedes the lease accounting guidance in ASC 840&#160;<i>Leases</i>&#160;and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. It also requires additional disclosures about leasing arrangements. The Company adopted ASC 842 on March 1, 2019 and used the modified retrospective transition approach and did not restate its comparative periods. As of the date of implementation on March 1, 2019, the impact of the adoption of ASC 842 resulted in the recognition of a right of use asset and lease payable obligation on the Company&#8217;s consolidated balance sheets of $2,360,787. As the right of use asset and the lease payable obligation were the same upon adoption of ASC 842, there was no cumulative effect impact on the Company&#8217;s accumulated deficit.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,&#160;<i>Revenue from Contracts with Customers</i>. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company&#8217;s financial statements and disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; Related Party Transactions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Due to related parties</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amounts loaned to the Company by stockholders and officers of the Company are non-interest bearing and payable upon demand. At May 31, 2019 and August 31, 2018, the amount due to related parties was $931,128 and $1,116,261, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2018, a related party converted $813,125 of outstanding principal and accrued interest into 1,976,483 shares of the Company&#8217;s common stock. The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; Other Receivables</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019 (currently in default)</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">277,312</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">286,763</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,580</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,588</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">73,950</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">76,470</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">55,463</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57,352</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">225,924</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total other receivables</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">662,229</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">451,173</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(577,186</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(393,821</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">85,043</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57,352</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; Property and Equipment</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold Improvements</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">444,449</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">372,010</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">274,395</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">269,741</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,890</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,636</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Office equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">26,658</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,658</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,315</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">39,620</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">805,707</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">728,665</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(387,410</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(328,344</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">418,297</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">400,321</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the nine months ended May 31, 2019 and 2018 was $71,256 and $52,287, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; Notes Payable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Notes payable at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31, 2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019. Currently in Dispute.</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">369,750</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">382,350</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">369,750</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">382,350</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(369,750</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(382,350</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 &#8211; Debentures, related parties</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 ($4,968,990 at November 30, 2017) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2018, the debenture holders converted 75% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 10,475,872 shares of the Company&#8217;s common stock. The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. At May 31, 2019, the amount of debentures outstanding was $1,183,664.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12 &#8211; Stockholders&#8217; Deficit</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Convertible preferred stock</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. At May 31, 2019 and August 31, 2018 there were 0 and 0 convertible preferred shares issued, outstanding and designated, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Common stock</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has authorized 499,000,000 shares of $0.001 par value common stock. At May 31, 2019 and August 31, 2018 there were 223,585,536 and 207,881,743 common shares issued and outstanding, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended May 31, 2019, the Company issued:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%">&#160;</td> <td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,245,444 restricted shares of common stock for cash proceeds of $3,228,098;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate; and</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock options/warrants</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 8, 2015, the Company adopted the 2015 Incentive Compensation Plan (the &#8220;2015 Plan&#8221;), which authorizes the issuance of up to 5,000,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. As of May 31, 2019, 4,987,500 shares were available under the 2015 Plan for future grants, awards, options or share issuances. However, because the shares issuable under the 2015 Plan or issuable upon conversion of awards granted under the 2015 Plan are no longer registered under the Securities Exchange Act of 1934, as amended, the Company does not intend to issue any additional grants under the 2015 Plan.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 16, 2018, the Company adopted the Novo Integrated Sciences, Inc. 2018 Incentive Plan (the &#8220;2018 Plan&#8221;). Under the 2018 Plan, 10,000,000 shares of common stock are authorized for issuance to employees, non-employees, directors and key consultants to the Company or its subsidiaries. The 2018 Plan authorizes equity-based and cash-based incentives for participants. There were 9,875,000 shares available for award at May 31, 2019 under the 2018 Plan.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of stock option/warrant activity:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options/</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, August 31, 2018</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,030,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.56</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,045,500</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">75,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(10,000</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,095,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,573,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable, May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,095,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,573,000</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise price for options/warrants outstanding at May 31, 2019:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding and Exercisable</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options/Warrants</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 48%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,500,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 46%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.16</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.32</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.33</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">120,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.40</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.42</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.62</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.80</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">75,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,095,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For options granted during the fiscal year ending August 31, 2019 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.94 and the weighted-average exercise price of such options/warrants was $0.95. No options were granted during the fiscal year ending August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For options granted during the fiscal year ended August 31, 2018 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.39 and the weighted-average exercise price of such options/warrants was $0.40. No options were granted during the fiscal year ended August 31, 2018 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $70,846 and $1,220,419 during the nine months ended May 31, 2019 and 2018, respectively. At May 31, 2019, the unamortized stock option expense was $0.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through May 31, 2019, are as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.78</font></td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of the options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.5 years</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">294</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 13 &#8211; Commitments and Contingencies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Litigation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company&#8217;s management to date, the Company&#8217;s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company&#8217;s consolidated financial position as of May 31, 2019, results of operations, cash flows or liquidity of the Company.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; line-height: 107%">&#160;</td> <td style="width: 48%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3 years</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Office equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019 (currently in default)</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">277,312</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">286,763</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,580</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,588</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">73,950</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">76,470</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">55,463</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57,352</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">225,924</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total other receivables</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">662,229</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">451,173</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(577,186</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(393,821</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">85,043</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57,352</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold Improvements</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">444,449</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">372,010</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">274,395</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">269,741</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,890</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,636</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Office equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">26,658</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,658</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,315</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">39,620</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">805,707</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">728,665</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(387,410</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(328,344</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">418,297</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">400,321</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Notes payable at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31, 2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019. Currently in Dispute.</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">369,750</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">382,350</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">369,750</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">382,350</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(369,750</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(382,350</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of stock option/warrant activity:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options/</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, August 31, 2018</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,030,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.56</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,045,500</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">75,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(10,000</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,095,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,573,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable, May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,095,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,573,000</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise price for options/warrants outstanding at May 31, 2019:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding and Exercisable</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options/Warrants</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 48%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,500,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 46%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.16</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.32</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.33</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">120,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.40</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.42</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.62</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.80</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">75,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,095,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through May 31, 2019, are as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.78</font></td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of the options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.5 years</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">294</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Principles of Consolidation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company&#8217;s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Noncontrolling Interest</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB ASC Topic 810,&#160;<i>Consolidation,</i>&#160;which governs the accounting for and reporting of non-controlling interests (&#8220;NCIs&#8221;) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent&#8217;s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cash Equivalents</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Accounts Receivable</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $475,329 and $464,527, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Property and Equipment</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; line-height: 107%">&#160;</td> <td style="width: 48%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3 years</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Office equipment</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Long-Lived Assets</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the provisions of ASC Topic 360,&#160;<i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at May 31, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Goodwill</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At May 31, 2019, the Company recorded goodwill of $369,750 and $214,455, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Acquisition Deposits</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has signed letters of understanding with three potential acquisition candidates which include refundable acquisition deposits totaling $1,445,495 and $1,112,404 at May 31, 2019 and August 31, 2018, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For certain of the Company&#8217;s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB ASC Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825,&#160;<i>Financial Instruments</i>, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%">&#160;</td> <td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480,&#160;<i>Distinguishing Liabilities from Equity</i>, and FASB ASC Topic 815,&#160;<i>Derivatives and Hedging</i>.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 31, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income Taxes</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;<i>Income Taxes</i>. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basic and Diluted Earnings Per Share</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings per share is calculated in accordance with ASC Topic 260,&#160;<i>Earnings Per Share</i>. Basic earnings per share (&#8220;EPS&#8221;) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of May 31, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Foreign Currency Transactions and Comprehensive Income</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company&#8217;s Canadian subsidiaries is the CAD. Translation gains of $1,102,188 and $1,139,815 at May 31, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders&#8217; equity section of the balance sheet.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Statement of Cash Flows</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flows from the Company&#8217;s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2016, the FASB issued ASU 2016-16,&#160;<i>Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory</i>, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU on March 1, 2019 with no material impact on the Company&#8217;s financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>&#160;. ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 and additional ASUs are now codified as Accounting Standards Codification Standard (&#8220;ASC&#8221;) 842 -&#160;<i>Leases</i>&#160;(&#8220;ASC 842&#8221;). ASC 842 supersedes the lease accounting guidance in ASC 840&#160;<i>Leases</i>&#160;and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. It also requires additional disclosures about leasing arrangements. The Company adopted ASC 842 on March 1, 2019 and used the modified retrospective transition approach and did not restate its comparative periods. As of the date of implementation on March 1, 2019, the impact of the adoption of ASC 842 resulted in the recognition of a right of use asset and lease payable obligation on the Company&#8217;s consolidated balance sheets of $2,360,787. As the right of use asset and the lease payable obligation were the same upon adoption of ASC 842, there was no cumulative effect impact on the Company&#8217;s accumulated deficit.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,&#160;<i>Revenue from Contracts with Customers</i>. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company&#8217;s financial statements and disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.</p> true false false <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 &#8211; Accrued Expenses</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued liabilities</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57,856</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">266,123</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued payroll</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">119,291</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">106,761</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,861</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,114</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">208,008</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">383,998</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14 &#8211; Subsequent Events</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 4, 2019, the Company sold 21,413 restricted shares of common stock to an accredited investor for a purchase price of $22,269.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivables, net at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Trade receivables</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,571,743</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,564,180</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Amounts earned but not billed</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">286,615</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">237,892</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,858,358</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,802,072</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for doubtful accounts</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(475,329</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(464,527</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,383,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,337,545</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued liabilities</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57,856</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">266,123</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued payroll</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">119,291</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">106,761</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,861</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,114</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">208,008</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">383,998</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 57352 85043 383998 208008 7001607 6722825 2489575 2323169 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table details the exchange rates used for the respective periods:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31, 2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Period end: CAD to USD exchange rate</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7395</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7712</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7647</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average period: CAD to USD exchange rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7540</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.7901</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock-Based Compensation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company records stock-based compensation in accordance with FASB ASC Topic 718,&#160;<i>Compensation &#8211; Stock Compensation</i>. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.</p> 13473 331 4090 120 136643 480981 41735 42696 225924 38929 22358567 22358567 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7 &#8211; Intangible Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31, 2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Land use rights</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,600,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Software license</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">758,567</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,358,567</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated amortization</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,358,567</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There was no amortization expense during the nine months ended May 31, 2019 and 2018 as the listed intangible assets have not been placed in service.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31, 2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Land use rights</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,600,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Software license</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">758,567</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,358,567</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated amortization</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,358,567</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 393821 577186 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue Recognition</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09,&#160;<i>Revenue from Contracts with Customers</i>&#160;(&#8220;Topic 606&#8221;), became effective for the Company on March 1, 2018. The Company&#8217;s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the &#8220;modified retrospective&#8221; transition method for open contracts for the implementation of Topic 606<i>.</i>&#160;As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company&#8217;s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605,&#160;<i>Revenue Recognition</i>.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">executed contracts with the Company&#8217;s customers that it believes are legally enforceable;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">identification of performance obligations in the respective contract;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">determination of the transaction price for each performance obligation in the respective contract;</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">allocation the transaction price to each performance obligation; and</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">recognition of revenue only when the Company satisfies each performance obligation.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These five elements, as applied to healthcare services, the Company&#8217;s sole revenue category, is summarized below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 107%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider&#8217;s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Intangible Assets</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.</p> Yes Yes false 2201893 2360787 413896 1183664 1789779 207881743 223585536 201837254 214698824 3245444 25104 3228098 15564 3245 25 3224853 15539 3228098 15564 70846 1220419 70846 1220419 70846 1220419 -36489 -94973 -37627 -95846 1138 873 -37627 -95846 384110 12452356 5122899 12453 5110446 5122899 31536 31536 31536 21600000 12000 21588000 21600000 12000000 31536 98316 142676 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 &#8211; Leases</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company&#8217;s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. Effective March 1, 2019, the Company adopted the provision of ASC 842 Leases.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the lease related assets and liabilities recorded on the Company&#8217;s consolidated balance sheets as of May 31, 2019:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Classification on Balance Sheet</b></font></td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>May 31, 2019</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 37%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease assets</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 39%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease right of use assets</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,201,893</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total lease assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,201,893</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Liabilities</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">413,896</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Noncurrent liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,789,779</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,203,675</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Lease obligations at May 31, 2019 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Twelve months ending May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">575,245</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">573,476</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">464,407</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">401,394</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">197,454</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">149,001</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">412,330</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total payments</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,773,307</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Amount representing interest</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(569,632</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Lease obligation, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,203,675</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less lease obligation, current portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(413,896</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Lease obligation, long-term portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,789,779</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The lease expense for the three months ended May 31, 2019 (since adoption of ASC 842) was $142,676, which consisted of amortization expense of $98,316 and interest expense of $44,360. The cash paid under operating leases during the three months ended May 31, 2019 was $115,311. At May 31, 2019, the weighted average remaining lease terms were 6.0 years and the weighted average discount rate was 8%</p> -96498 Delaware 2000-11-27 3245444 167797406 12000000 458349 21413 0.85 0.7647 0.7395 0.7712 0.7540 0.7901 0.80 464527 475329 P7Y P50Y 10095000 2203675 2360787 P5Y P5Y P3Y P5Y P5Y 813125 1976483 10475872 The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. 0.4114 0.4114 1564180 1571743 237892 286615 1802072 1858358 451173 277312 29580 73950 286763 30588 76470 57352 55463 662229 225924 0.08 0.08 0.12 0.12 0.10 0.10 0.10 2019-03-01 2019-03-01 2019-09-30 2019-09-30 2022-05-01 2022-05-01 2020-11-18 2020-11-18 2020-02-07 728665 372010 269741 22636 24658 39620 805707 444449 274395 21890 26658 38315 328344 387410 22358567 21600000 758567 266123 57856 106761 119291 11114 30861 382350 382350 369750 369750 0.00 0.00 2019-03-27 2019-03-27 2016-09-30 0.08 2019-09-30 0.75 2028 98316 44360 115311 P6Y 0.08 2201893 575245 573476 464407 401394 197454 149001 412330 2773307 569632 3228098 21600000 758567 22269 1.80 1.655 5000000 10000000 0.39 0.94 0.40 0.95 70846 1220419 0 10030000 10095000 75000 10000 10095000 0.30 0.30 0.95 2.00 0.30 P4Y6M21D P3Y9M29D P3Y9M29D 7045500 9573000 9573000 5500000 1000000 50000 120000 2000000 100000 1000000 250000 75000 10095000 0.16 0.32 0.33 0.40 0.42 0.50 0.62 0.80 0.95 5500000 1000000 50000 120000 2000000 100000 1000000 250000 75000 10095000 0.16 0.32 0.33 0.40 0.42 0.50 0.62 0.80 0.95 0.0278 P3Y6M 2.94 0.00 377000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the lease related assets and liabilities recorded on the Company&#8217;s consolidated balance sheets as of May 31, 2019:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Classification on Balance Sheet</b></font></td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>May 31, 2019</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 37%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease assets</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 39%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease right of use assets</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,201,893</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total lease assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,201,893</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Liabilities</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">413,896</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Noncurrent liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term operating lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,789,779</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total lease liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,203,675</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Lease obligations at May 31, 2019 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Twelve months ending May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">575,245</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">573,476</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">464,407</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">401,394</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">197,454</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">149,001</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">412,330</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total payments</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,773,307</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Amount representing interest</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(569,632</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Lease obligation, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,203,675</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less lease obligation, current portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(413,896</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Lease obligation, long-term portion</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,789,779</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 758567 458 758109 758567 -70846 -1220419 1802598 -1032876 1896572 675705 2478303 863696 -37309 -46881 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; Accounts Receivables, net</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivables, net at May 31, 2019 and August 31, 2018 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">May 31,</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 31,</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Trade receivables</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,571,743</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,564,180</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Amounts earned but not billed</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">286,615</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">237,892</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,858,358</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,802,072</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for doubtful accounts</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(475,329</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(464,527</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,383,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,337,545</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 9875000 4987500 458349 EX-101.SCH 6 nvos-20190531.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Receivables, Net link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Other Receivables link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Debentures, Related Parties link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Organization and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Accounts Receivables, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Other Receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Organization and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Debentures, Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Leases - Schedule of Lease Related Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Leases - Schedule of Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nvos-20190531_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 nvos-20190531_def.xml XBRL DEFINITION FILE EX-101.LAB 9 nvos-20190531_lab.xml XBRL LABEL FILE Legal Entity [Axis] Turbine Truck Engines, Inc [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Share Exchange Agreement [Member] NHL [Member] Receivable Type [Axis] Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member] Advance to Corporation One [Member] Advance to Corporation Two [Member] Property, Plant and Equipment, Type [Axis] Leasehold Improvements [Member] Clinical Equipment [Member] Computer Equipment [Member] Office Equipment [Member] Furniture and Fixtures [Member] Debt Instrument [Axis] Notes Payable [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member] Five Debentures [Member] Award Type [Axis] CAD [Member] Plan Name [Axis] 2015 Incentive Compensation Plan [Member] Range [Axis] Maximum [Member] Exercise Price Range Six [Member] Award Date [Axis] Period End [Member] Average Period [Member] Exercise Price Range Seven [Member] 2018 Incentive Plan [Member] Exercise Price Range Eight [Member] Exercise Price Range Nine [Member] Debentures [Member] Advance to Corporation Three [Member] August 31, 2019 [Member] Novo Healthnet Kemptville Centre, Inc. [Member] Business Acquisition [Axis] Apka Health, Inc. [Member] Executive Fitness Leaders [Member] Finite-Lived Intangible Assets by Major Class [Axis] Software License [Member] Land Use Rights [Member] Advance to Corporation Four [Member] Joint Venture Agreement [Member] Licensing Agreement [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Other Comprehensive Income [Member] Noncontrolling Interest [Member] Accumulated Deficit [Member] Total Novo Stockholders' Equity/ (Deficit) [Member] Adjustments for New Accounting Pronouncements [Axis] ASC 842 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Title of Individual [Axis] Accredited Investor [Member] Consolidated Entities [Axis] Parent Company [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity's Reporting Status Current Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable, net Other receivables, current portion Prepaid expenses and other current assets Total current assets Property and equipment, net Intangible assets Right-of-use assets Other receivables, net of current portion Acquisition deposits Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Accrued expenses Accrued interest (principally to related parties) Due to related parties Notes payable, current portion Debentures, related parties Operating lease liability, current portion Total current liabilities Debentures, related parties Operating lease liability, net of current portion TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS' EQUITY Novo Integrated Sciences, Inc. Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2019 and August 31, 2018 Common stock; $0.001par value; 499,000,000 shares authorized; 223,585,536 and 207,881,743 shares issued and outstanding at May 31, 2019 and August 31, 2018 Additional paid-in capital Other comprehensive income Accumulated deficit Total Novo Integrated Sciences, Inc. stockholders' equity Noncontrolling interest Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses: Selling expenses General and administrative expenses Total operating expenses Loss from operations Non operating income (expense) Interest income Interest expense Total other income (expense) Loss before income taxes Income tax expense Net loss Net loss attributed to noncontrolling interest Net loss attributed to Novo Integrated Sciences, Inc. Comprehensive loss: Net loss Foreign currency translation gain (loss) Comprehensive loss: Weighted average common shares outstanding - basic and diluted Net loss per common share - basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Common stock issued for cash Common stock issued for cash, shares Common stock issued for acquisition Common stock issued for acquisition, shares Common stock issued for conversion of debt Common stock issued for conversion of debt, shares Common stock issued for interest in joint venture Common stock issued for interest in joint venture, shares Common stock issued for software license Common stock issued for software license, shares Fair value of vested stock options Fair value of modification of stock option terms Foreign currency translation loss Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Fair value of vested stock options Expense associated with modified stock option terms Operating lease expense Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable Accrued expenses Accrued interest Operating lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of furniture and equipment Payment for acquisition deposit Amounts loaned for other receivables Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayments to related parties Proceeds from the sale of common stock Payments on notes payable Net cash provided by (used in) financing activities Effect of exchange rate changes on cash and cash equivalents NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD CASH PAID FOR: Interest Income taxes SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: Common stock issued for intangible assets Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Basis of Presentation Accounting Policies [Abstract] Summary of Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Receivables [Abstract] Accounts Receivables, Net Other Receivables Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Notes Payable Debentures, Related Parties Leases [Abstract] Leases Equity [Abstract] Stockholders' Deficit Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Use of Estimates Principles of Consolidation Noncontrolling Interest Cash Equivalents Accounts Receivable Property and Equipment Long-Lived Assets Intangible Assets Goodwill Acquisition Deposits Fair Value of Financial Instruments Revenue Recognition Income Taxes Stock-Based Compensation Basic and Diluted Earnings Per Share Foreign Currency Transactions and Comprehensive Income Statement of Cash Flows Recent Accounting Pronouncements Schedule of Foreign Currency Translation, Exchange Rate Used Schedule of Estimated Useful Lives of Assets Schedule of Accounts Receivables, Net Schedule of Other Receivables Schedule of Property and Equipment Schedule of Intangible Assets Schedule of Accrued Expenses Schedule of Notes Payable Schedule of Lease Related Assets and Liabilities Schedule of Lease Obligations Schedule of Stock Option and Warrant Activity Schedule of Options and Warrants Outstanding and Exercisable Schedule of Fair Value of Options Granted by Using Valuation Assumptions Collaborative Arrangement and Arrangement Other than Collaborative [Axis] State country name Date of incorporation Number of restricted shares of common stock Percentage of common stock issued and outstanding Common stock issued in connection with reverse merger transaction Foreign currency exchange rate Equity method investment, ownership percentage Allowance for uncollectible accounts receivable Impairment of its long-lived assets Intangible asset, useful life amortized over term Refundable acquisition deposits Potentially dilutive common stock options and warrants outstanding, shares Translation gains Right of use asset Lease payable obligation Cumulative effect on retained earnings Property and equipment, estimated lives Related party debt, converted amount Debt converted, shares issued Debt conversion, description Debt conversion price Trade receivables Amounts earned but not billed Accounts receivable, gross Allowance for doubtful accounts Accounts receivable, net Total other receivables Current portion Long-term portion Percentage of interest accrued per annum Notes receivable due date Depreciation expense Property and equipment, gross Accumulated depreciation Total Amortization expense Intangible assets, gross Accumulated amortization Total Accrued liabilities Accrued payroll Other Accrued expenses Notes payable Current portion Long-term portion Percentage of interest accrued per annum Notes payable, due date Debentures, outstanding Debt interest rate Debt due date Debt extended due date Percentage of debt converted Accrued interest Operating leases expiration date Lease expense Amortization expense Interest expense Cash paid under operating leases Weighted average remaining lease terms Weighted average discount rate Operating lease assets Total lease assets Current liabilities- Operating lease liability Noncurrent liabilities - Operating lease liability Total lease liability 2020 2021 2022 2023 2024 2025 Thereafter Total payments Amount representing interest Lease obligation, net Less lease obligation, current portion Lease obligation, long-term portion Statistical Measurement [Axis] Number of restricted shares issued Proceeds from issuance of restricted shares Shares issued price per share Number of common stock shares issued Number of shares available for future grant Stock options granted weighted-average grant date fair value Stock options/warrants weighted-average exercise price Stock option expense Unamortized stock option expense Options/Warrants Outstanding, Beginning Balance Options/Warrants Outstanding, Granted Options/Warrants Outstanding, Forfeited Options/Warrants Outstanding, Exercised Options/Warrants Outstanding, Ending Balance Options/Warrants Outstanding, Exercisable Weighted Average Exercise Price, Outstanding, Beginning Balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Forfeited Weighted Average Exercise Price, Outstanding, Ending Balance Weighted Average Exercise Price, Exercisable Weighted Average Remaining Contractual Life, Outstanding, Beginning Balance Weighted Average Remaining Contractual Life, Outstanding, Ending Balance Weighted Average Remaining Contractual Life, Exercisable Aggregate Intrinsic Value, Outstanding, Beginning Balance Aggregate Intrinsic Value, Outstanding, Ending Balance Aggregate Intrinsic Value, Exercisable Number of Options/Warrants, Outstanding Number of Options/Warrants, Outstanding, Exercise Price Number of Options/Warrants, Exercisable Number of Options/Warrants, Exercisable, Exercise Price Risk-free interest rate Expected life of the options Expected volatility Expected dividend yield Number of restricted shares sold Purchase price of restricted shares Accredited Investor [Member] Acquisition deposits [Policy Text Block] Advance to Corporation Four [Member] Advance to Corporation One [Mermber] Advance to Corporation Three [Member] Advance to Corporation Two [Mermber] Apka Health, Inc. [Member] August 31, 2019 [Member] Average Period [Member] CAD [Member] CannaPiece Group Inc. [Member] Clinical Equipment [Member] Common stock issued for intangible assets. Debentures [Member] Debentures, related parties disclosure [Text Block] Executive Fitness Leaders [Member] Exercise Price Range Eight [Member] Exercise Price Range Five [Member] Exercise Price Range Four [Member] Exercise Price Range Nine [Member] Exercise Price Range One [Member] Exercise Price Range Seven [Member] Exercise Price Range Six [Member] Exercise Price Range Ten [Member] Exercise Price Range Three [Member] Exercise Price Range Two [Member] Five Debentures [Member] January 2019 [Member] Joint Venture Agreement [Member] Land Use Rights [Member] Licensing Agreement [Member] NHL [Member] Noncontrolling interest disclosure [Policy Text Block] Notes Payable [Member] Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member] Novo Healthnet Kemptville Centre, Inc [Member] Period End [Member] Restricted Common Stock [Member] Schedule of estimated useful lives of assets [Table Text Block] Schedule of other receivables [Table Text Block] Share Exchange Agreement [Member] Software License [Member] Statement of cash flows disclosure [Policy Text Block] Subscription Agreements [Member] Turbine Truck Engines, Inc [Member] Turbine Truck Engines, Inc One [Member] 2018 Incentiven Plan [Member] 2015 Incentive Compensation Plan [Member] Total Novo Stockholders' Equity/ (Deficit) [Member] Fair value of modification of stock option terms. Expense associated with modified stock option terms. Schedule of Lease Related Assets and Liabilities [Table Text Block] Schedule of Lease Obligations [Table Text Block] Operating lease liability. Incorporation, state country name. Percentage of common stock issued and outstanding. The total amount due to the entity within one year of the balance sheet date. Debt extended due date. Operating leases expiration date. Operating lease, amortization expense. Operating lease, interest expense. Operating lease assets. Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date. Amount of lessee's undiscounted obligation for lease payments for operating lease, due after sixth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Common stock issued for software license. Fair value of vested stock options. Common stock issued for software license, shares. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Other Nonoperating Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments for Previous Acquisition Payments for (Proceeds from) Loans Receivable Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Property, Plant and Equipment, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Accounts Receivable, before Allowance for Credit Loss, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Debt Instrument, Interest Rate During Period OperatingLeaseAmortizationExpense OperatingLeaseAssets Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value EX-101.PRE 10 nvos-20190531_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information - shares
9 Months Ended
May 31, 2019
Jul. 05, 2019
Document And Entity Information    
Entity Registrant Name Novo Integrated Sciences, Inc.  
Entity Central Index Key 0001138978  
Document Type 10-Q  
Document Period End Date May 31, 2019  
Amendment Flag false  
Current Fiscal Year End Date --08-31  
Entity's Reporting Status Current Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   223,606,949
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2019  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
May 31, 2019
Aug. 31, 2018
Current Assets:    
Cash and cash equivalents $ 2,478,303 $ 675,705
Accounts receivable, net 1,383,029 1,337,545
Other receivables, current portion 577,186 393,821
Prepaid expenses and other current assets 149,718 161,838
Total current assets 4,588,236 2,568,909
Property and equipment, net 418,297 400,321
Intangible assets 22,358,567
Right-of-use assets 2,201,893
Other receivables, net of current portion 85,043 57,352
Acquisition deposits 1,445,495 1,112,404
Goodwill 584,205 604,113
TOTAL ASSETS 31,681,736 4,743,099
Current Liabilities:    
Accounts payable 1,283,735 1,307,599
Accrued expenses 208,008 383,998
Accrued interest (principally to related parties) 188,321 156,121
Due to related parties 931,128 1,116,261
Notes payable, current portion 369,750 382,350
Debentures, related parties 1,183,664
Operating lease liability, current portion 413,896
Total current liabilities 4,578,502 3,346,329
Debentures, related parties 1,224,000
Operating lease liability, net of current portion 1,789,779
TOTAL LIABILITIES 6,368,281 4,570,329
Commitments and contingencies
Novo Integrated Sciences, Inc.    
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2019 and August 31, 2018
Common stock; $0.001par value; 499,000,000 shares authorized; 223,585,536 and 207,881,743 shares issued and outstanding at May 31, 2019 and August 31, 2018 223,585 207,882
Additional paid-in capital 35,695,491 10,053,683
Other comprehensive income 1,102,188 1,139,815
Accumulated deficit (11,670,164) (11,199,989)
Total Novo Integrated Sciences, Inc. stockholders' equity 25,351,100 201,391
Noncontrolling interest (37,645) (28,621)
Total stockholders' equity 25,313,455 172,770
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 31,681,736 $ 4,743,099
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
May 31, 2019
Aug. 31, 2018
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value $ 0.001 $ 0.001
Convertible preferred stock, shares authorized 1,000,000 1,000,000
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 499,000,000 499,000,000
Common stock, shares issued 223,585,536 207,881,743
Common stock, shares outstanding 223,585,536 207,881,743
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
May 31, 2019
May 31, 2018
May 31, 2019
May 31, 2018
Income Statement [Abstract]        
Revenues $ 2,489,575 $ 2,323,169 $ 7,001,607 $ 6,722,825
Cost of revenues 1,556,865 1,417,999 4,305,688 4,133,288
Gross profit 932,710 905,170 2,695,919 2,589,537
Operating expenses:        
Selling expenses 3,846 17,900 33,085 86,640
General and administrative expenses 991,992 1,064,107 3,020,001 3,978,861
Total operating expenses 995,838 1,082,007 3,053,086 4,065,501
Loss from operations (63,128) (176,837) (357,167) (1,475,964)
Non operating income (expense)        
Interest income 4,090 120 13,473 331
Interest expense (41,735) (42,696) (136,643) (480,981)
Total other income (expense) (37,645) (42,576) (123,170) (480,650)
Loss before income taxes (100,773) (219,413) (480,337) (1,956,614)
Income tax expense
Net loss (100,773) (219,413) (480,337) (1,956,614)
Net loss attributed to noncontrolling interest (1,515) (1,515) (10,162) (6,871)
Net loss attributed to Novo Integrated Sciences, Inc. (99,258) (217,898) (470,175) (1,949,743)
Comprehensive loss:        
Net loss (100,773) (219,413) (480,337) (1,956,614)
Foreign currency translation gain (loss) (63,607) (8,505) (37,627) (95,846)
Comprehensive loss: $ (164,380) $ (227,918) $ (517,964) $ (2,052,460)
Weighted average common shares outstanding - basic and diluted 223,258,368 214,684,089 215,193,998 207,568,978
Net loss per common share - basic and diluted $ (0.00) $ (0.00) $ (0.00) $ (0.01)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Total Novo Stockholders' Equity/ (Deficit) [Member]
Noncontrolling Interest [Member]
Total
Balance at Aug. 31, 2017 $ 201,837 $ 3,381,643 $ (9,091,977) $ (5,508,497) $ (20,537) $ (5,529,034)
Balance, shares at Aug. 31, 2017 201,837,254            
Common stock issued for cash $ 25 15,539 15,564 15,564
Common stock issued for cash, shares 25,104            
Common stock issued for acquisition $ 384 232,771 233,155 233,155
Common stock issued for acquisition, shares 384,110            
Common stock issued for conversion of debt $ 12,453 5,110,446 5,122,899 5,122,899
Common stock issued for conversion of debt, shares 12,452,356            
Fair value of vested stock options 1,220,419 1,220,419 1,220,419
Fair value of modification of stock option terms 31,536 31,536 31,536
Foreign currency translation loss (95,846) (95,846) 873 (94,973)
Net loss (1,949,743) (1,949,743) (6,871) (1,956,614)
Balance at May. 31, 2018 $ 214,699 9,992,354 (95,846) (11,041,720) (930,513) (26,535) (957,048)
Balance, shares at May. 31, 2018 214,698,824            
Balance at Aug. 31, 2018 $ 207,882 10,053,683 1,139,815 (11,199,989) 201,391 (28,621) 172,770
Balance, shares at Aug. 31, 2018 207,881,743            
Common stock issued for cash $ 3,245 3,224,853 3,228,098 3,228,098
Common stock issued for cash, shares 3,245,444            
Common stock issued for interest in joint venture $ 12,000 21,588,000 21,600,000 21,600,000
Common stock issued for interest in joint venture, shares 12,000,000            
Common stock issued for software license $ 458 758,109 758,567 758,567
Common stock issued for software license, shares 458,349            
Fair value of vested stock options 70,846 70,846 70,846
Foreign currency translation loss (37,627) (37,627) 1,138 (36,489)
Net loss (470,175) (470,175) (10,162) (480,337)
Balance at May. 31, 2019 $ 223,585 $ 35,695,491 $ 1,102,188 $ (11,670,164) $ 25,351,100 $ (37,645) $ 25,313,455
Balance, shares at May. 31, 2019 223,585,536            
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
May 31, 2019
May 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (480,337) $ (1,956,614)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 71,256 52,287
Fair value of vested stock options 70,846 1,220,419
Expense associated with modified stock option terms 31,536
Operating lease expense 98,316
Changes in operating assets and liabilities:    
Accounts receivable (91,318) (227,113)
Prepaid expenses and other current assets 7,182 39,503
Accounts payable 18,628 (343,102)
Accrued expenses (167,126) 39,552
Accrued interest 38,076 303,488
Operating lease liability (96,498)
Net cash used in operating activities (530,975) (840,044)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and equipment (103,035) (83,950)
Payment for acquisition deposit (377,000)
Amounts loaned for other receivables (225,924) (38,929)
Net cash used in investing activities (705,959) (122,879)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayments to related parties (151,257) (31,580)
Proceeds from the sale of common stock 3,228,098 15,564
Payments on notes payable (7,056)
Net cash provided by (used in) financing activities 3,076,841 (23,072)
Effect of exchange rate changes on cash and cash equivalents (37,309) (46,881)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,802,598 (1,032,876)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 675,705 1,896,572
CASH AND CASH EQUIVALENTS, END OF PERIOD 2,478,303 863,696
CASH PAID FOR:    
Interest 104,443 170,588
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Common stock issued for intangible assets $ 22,358,567
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Organization and Basis of Presentation
9 Months Ended
May 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

 

Organization and Line of Business

 

Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.

 

Through Novo Healthnet Limited (“NHL”), our wholly owned Canadian subsidiary, we deliver multi-disciplinary primary healthcare to over 400,000 patients annually through our 15 corporate-owned clinics and a contracted network of 96 affiliate clinics and 229 eldercare centric homes located across Canada. Our team of practitioners and staff are trained for assessment, diagnosis, treatment, pain management, rehabilitation and primary prevention. Our specialized services and products include physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropody, neurological functions, kinesiology, concussion management and baseline testing, women’s pelvic health, sports medicine therapy, assistive devices and private personal training. We do not provide primary care medical services, none of our employees practices primary care medicine, and our services do not require a medical or nursing license.

 

As we continue to build our health science platform of services and products through the integration of technology and rehabilitative science, one component of our lateral business growth strategy includes developing business units centered on the direct control of the grow, extraction, manufacturing and distribution processes for hemp and medical cannabidiol products. Additionally, we continue to expand on our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of a clinic, by extending oversight of patient diagnosis, care and monitoring, directly into the patient’s home, through various mobile telemedicine and diagnostic tools.

 

Since inception and through May 9, 2017, our activities and business operations were limited to raising capital, organizational matters and the implementation of our business plan related to research, development, testing and commercialization of various alternative energy technologies.

 

On April 25, 2017 (the “Effective Date”), the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) the Company; (ii) NHL; (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, the Company agreed to acquire from the NHL Shareholders all of the shares of both common and preferred stock of NHL, held by the NHL Shareholders, in exchange for the issuance by the Company to the NHL Shareholders of shares of the Company’s common stock, such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 167,797,406 restricted shares of Company common stock, representing 85% of the issued and outstanding Company common stock, calculated including all granted and issued options or warrants to acquire the Company common stock as of the Effective Date, but to exclude shares of Company common stock that are subject to a then-current Regulation S offering that was undertaking by the Company (the “Exchange”).

 

On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated Sciences, Inc.

 

The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Exchange was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904.

 

The unaudited consolidated financial statements are prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) were omitted pursuant to such rules and regulations. The results of operations for the nine months ended May 31, 2019 are not necessarily indicative of the results for the year ending August 31, 2019.

 

Basis of Presentation

 

The accompanying consolidated financial statements were prepared in conformity with U.S. GAAP. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD” or “CAD$”); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”).

 

Foreign Currency Translation

 

The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction, with the CAD as the functional currency. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income. The following table details the exchange rates used for the respective periods:

 

    May 31, 2019     May 31, 2018     August 31, 2018  
Period end: CAD to USD exchange rate   $ 0.7395     $ 0.7712     $ 0.7647  
Average period: CAD to USD exchange rate   $ 0.7540     $ 0.7901          

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies
9 Months Ended
May 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company’s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.

 

Noncontrolling Interest

 

The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

 

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

 

Cash Equivalents

 

For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

 

Accounts Receivable

 

Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $475,329 and $464,527, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

 

  Leasehold improvements 5 years
  Clinical equipment 5 years
  Computer equipment 3 years
  Office equipment 5 years
  Furniture and fixtures 5 years

 

Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at May 31, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.

 

Intangible Assets

 

The Company’s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.

 

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At May 31, 2019, the Company recorded goodwill of $369,750 and $214,455, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.

 

Acquisition Deposits

 

The Company has signed letters of understanding with three potential acquisition candidates which include refundable acquisition deposits totaling $1,445,495 and $1,112,404 at May 31, 2019 and August 31, 2018, respectively.

 

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

 

  Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
     
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
     
  Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

 

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

 

As of May 31, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

 

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;
  identification of performance obligations in the respective contract;
  determination of the transaction price for each performance obligation in the respective contract;
  allocation the transaction price to each performance obligation; and
  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

 

  Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of May 31, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.

 

Foreign Currency Transactions and Comprehensive Income

 

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,102,188 and $1,139,815 at May 31, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

 

Statement of Cash Flows

 

Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

Recent Accounting Pronouncements

 

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU on March 1, 2019 with no material impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 and additional ASUs are now codified as Accounting Standards Codification Standard (“ASC”) 842 - Leases (“ASC 842”). ASC 842 supersedes the lease accounting guidance in ASC 840 Leases and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. It also requires additional disclosures about leasing arrangements. The Company adopted ASC 842 on March 1, 2019 and used the modified retrospective transition approach and did not restate its comparative periods. As of the date of implementation on March 1, 2019, the impact of the adoption of ASC 842 resulted in the recognition of a right of use asset and lease payable obligation on the Company’s consolidated balance sheets of $2,360,787. As the right of use asset and the lease payable obligation were the same upon adoption of ASC 842, there was no cumulative effect impact on the Company’s accumulated deficit.

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.

 

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Related Party Transactions
9 Months Ended
May 31, 2019
Related Party Transactions [Abstract]  
Related Party Transactions

Note 3 – Related Party Transactions

 

Due to related parties

 

Amounts loaned to the Company by stockholders and officers of the Company are non-interest bearing and payable upon demand. At May 31, 2019 and August 31, 2018, the amount due to related parties was $931,128 and $1,116,261, respectively.

 

On January 31, 2018, a related party converted $813,125 of outstanding principal and accrued interest into 1,976,483 shares of the Company’s common stock. The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Accounts Receivables, Net
9 Months Ended
May 31, 2019
Receivables [Abstract]  
Accounts Receivables, Net

Note 4 – Accounts Receivables, net

 

Accounts receivables, net at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Trade receivables   $ 1,571,743     $ 1,564,180  
Amounts earned but not billed     286,615       237,892  
      1,858,358       1,802,072  
Allowance for doubtful accounts     (475,329 )     (464,527 )
Accounts receivable, net   $ 1,383,029     $ 1,337,545  

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Other Receivables
9 Months Ended
May 31, 2019
Receivables [Abstract]  
Other Receivables

Note 5 – Other Receivables

 

Other receivables at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019 (currently in default)   $ 277,312     $ 286,763  
Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020     29,580       30,588  
Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019     73,950       76,470  
Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022     55,463       57,352  
Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020     225,924       -  
Total other receivables     662,229       451,173  
Current portion     (577,186 )     (393,821 )
Long-term portion   $ 85,043     $ 57,352  

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment
9 Months Ended
May 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 6 – Property and Equipment

 

Property and equipment at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Leasehold Improvements   $ 444,449     $ 372,010  
Clinical equipment     274,395       269,741  
Computer equipment     21,890       22,636  
Office equipment     26,658       24,658  
Furniture and fixtures     38,315       39,620  
      805,707       728,665  
Accumulated depreciation     (387,410 )     (328,344 )
Total   $ 418,297     $ 400,321  

 

Depreciation expense for the nine months ended May 31, 2019 and 2018 was $71,256 and $52,287, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets
9 Months Ended
May 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 7 – Intangible Assets

 

Intangible assets at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31, 2019     August 31, 2018  
Land use rights   $ 21,600,000     $ -  
Software license     758,567       -  
      22,358,567       -  
Accumulated amortization     -       -  
Total   $ 22,358,567     $ -  

 

There was no amortization expense during the nine months ended May 31, 2019 and 2018 as the listed intangible assets have not been placed in service.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Expenses
9 Months Ended
May 31, 2019
Payables and Accruals [Abstract]  
Accrued Expenses

Note 8 – Accrued Expenses

 

Accrued expenses at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Accrued liabilities   $ 57,856     $ 266,123  
Accrued payroll     119,291       106,761  
Other     30,861       11,114  
    $ 208,008     $ 383,998  

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable
9 Months Ended
May 31, 2019
Debt Disclosure [Abstract]  
Notes Payable

Note 9 – Notes Payable

 

Notes payable at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31, 2019     August 31, 2018  
Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019. Currently in Dispute.   $ 369,750     $ 382,350  
      369,750       382,350  
Current portion     (369,750 )     (382,350 )
Long-term portion   $ -     $ -  

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Debentures, Related Parties
9 Months Ended
May 31, 2019
Debt Disclosure [Abstract]  
Debentures, Related Parties

Note 10 – Debentures, related parties

 

On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 ($4,968,990 at November 30, 2017) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019.

 

On January 31, 2018, the debenture holders converted 75% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 10,475,872 shares of the Company’s common stock. The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. At May 31, 2019, the amount of debentures outstanding was $1,183,664.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Leases
9 Months Ended
May 31, 2019
Leases [Abstract]  
Leases

Note 11 – Leases

 

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate.

 

The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. Effective March 1, 2019, the Company adopted the provision of ASC 842 Leases.

 

The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of May 31, 2019:

 

    Classification on Balance Sheet   May 31, 2019  
Assets          
Operating lease assets   Operating lease right of use assets   $ 2,201,893  
Total lease assets       $ 2,201,893  
             
Liabilities            
Current liabilities            
Operating lease liability   Current operating lease liability   $ 413,896  
Noncurrent liabilities            
Operating lease liability   Long-term operating lease liability     1,789,779  
Total lease liability       $ 2,203,675  

 

Lease obligations at May 31, 2019 consisted of the following:

 

Twelve months ending May 31,      
2020   $ 575,245  
2021     573,476  
2022     464,407  
2023     401,394  
2024     197,454  
2025     149,001  
Thereafter     412,330  
Total payments     2,773,307  
Amount representing interest     (569,632 )
Lease obligation, net     2,203,675  
Less lease obligation, current portion     (413,896 )
Lease obligation, long-term portion   $ 1,789,779  

 

The lease expense for the three months ended May 31, 2019 (since adoption of ASC 842) was $142,676, which consisted of amortization expense of $98,316 and interest expense of $44,360. The cash paid under operating leases during the three months ended May 31, 2019 was $115,311. At May 31, 2019, the weighted average remaining lease terms were 6.0 years and the weighted average discount rate was 8%

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Deficit
9 Months Ended
May 31, 2019
Equity [Abstract]  
Stockholders' Deficit

Note 12 – Stockholders’ Deficit

 

Convertible preferred stock

 

The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. At May 31, 2019 and August 31, 2018 there were 0 and 0 convertible preferred shares issued, outstanding and designated, respectively.

 

Common stock

 

The Company has authorized 499,000,000 shares of $0.001 par value common stock. At May 31, 2019 and August 31, 2018 there were 223,585,536 and 207,881,743 common shares issued and outstanding, respectively.

 

During the nine months ended May 31, 2019, the Company issued:

 

  3,245,444 restricted shares of common stock for cash proceeds of $3,228,098;
     
  12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate; and
     
  458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567.

 

Stock options/warrants

 

On September 8, 2015, the Company adopted the 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 5,000,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. As of May 31, 2019, 4,987,500 shares were available under the 2015 Plan for future grants, awards, options or share issuances. However, because the shares issuable under the 2015 Plan or issuable upon conversion of awards granted under the 2015 Plan are no longer registered under the Securities Exchange Act of 1934, as amended, the Company does not intend to issue any additional grants under the 2015 Plan.

 

On January 16, 2018, the Company adopted the Novo Integrated Sciences, Inc. 2018 Incentive Plan (the “2018 Plan”). Under the 2018 Plan, 10,000,000 shares of common stock are authorized for issuance to employees, non-employees, directors and key consultants to the Company or its subsidiaries. The 2018 Plan authorizes equity-based and cash-based incentives for participants. There were 9,875,000 shares available for award at May 31, 2019 under the 2018 Plan.

  

The following is a summary of stock option/warrant activity:

 

                Weighted        
          Weighted     Average        
    Options/     Average     Remaining     Aggregate  
    Warrants     Exercise     Contractual     Intrinsic  
    Outstanding     Price     Life     Value  
Outstanding, August 31, 2018     10,030,000       0.30       4.56     $ 7,045,500  
Granted     75,000       0.95                  
Forfeited     (10,000 )     2.00                  
Exercised     -                          
Outstanding, May 31, 2019     10,095,000       0.30       3.83     $ 9,573,000  
Exercisable, May 31, 2019     10,095,000     $ 0.30       3.83     $ 9,573,000  

 

The exercise price for options/warrants outstanding at May 31, 2019:

 

Outstanding and Exercisable  
Number of     Exercise  
Options/Warrants     Price  
  5,500,000     $ 0.16  
  1,000,000       0.32  
  50,000       0.33  
  120,000       0.40  
  2,000,000       0.42  
  100,000       0.50  
  1,000,000       0.62  
  250,000       0.80  
  75,000       0.95  
  10,095,000          

 

For options granted during the fiscal year ending August 31, 2019 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.94 and the weighted-average exercise price of such options/warrants was $0.95. No options were granted during the fiscal year ending August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

 

For options granted during the fiscal year ended August 31, 2018 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.39 and the weighted-average exercise price of such options/warrants was $0.40. No options were granted during the fiscal year ended August 31, 2018 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

 

The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $70,846 and $1,220,419 during the nine months ended May 31, 2019 and 2018, respectively. At May 31, 2019, the unamortized stock option expense was $0.

  

The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through May 31, 2019, are as follows:

 

Risk-free interest rate     2.78 %
Expected life of the options     3.5 years  
Expected volatility     294 %
Expected dividend yield     0 %

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies
9 Months Ended
May 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 13 – Commitments and Contingencies

 

Litigation

 

The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position as of May 31, 2019, results of operations, cash flows or liquidity of the Company.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent Events
9 Months Ended
May 31, 2019
Subsequent Events [Abstract]  
Subsequent Events

Note 14 – Subsequent Events

 

On June 4, 2019, the Company sold 21,413 restricted shares of common stock to an accredited investor for a purchase price of $22,269.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
May 31, 2019
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company’s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.

Noncontrolling Interest

Noncontrolling Interest

 

The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

 

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

Cash Equivalents

Cash Equivalents

 

For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

Accounts Receivable

Accounts Receivable

 

Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $475,329 and $464,527, respectively.

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

 

  Leasehold improvements 5 years
  Clinical equipment 5 years
  Computer equipment 3 years
  Office equipment 5 years
  Furniture and fixtures 5 years

Long-Lived Assets

Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at May 31, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.

Intangible Assets

Intangible Assets

 

The Company’s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.

Goodwill

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At May 31, 2019, the Company recorded goodwill of $369,750 and $214,455, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.

Acquisition Deposits

Acquisition Deposits

 

The Company has signed letters of understanding with three potential acquisition candidates which include refundable acquisition deposits totaling $1,445,495 and $1,112,404 at May 31, 2019 and August 31, 2018, respectively.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

 

  Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
     
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
     
  Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

 

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

 

As of May 31, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

Revenue Recognition

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;
  identification of performance obligations in the respective contract;
  determination of the transaction price for each performance obligation in the respective contract;
  allocation the transaction price to each performance obligation; and
  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

 

  Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

Stock-Based Compensation

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

Basic and Diluted Earnings Per Share

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of May 31, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.

Foreign Currency Transactions and Comprehensive Income

Foreign Currency Transactions and Comprehensive Income

 

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,102,188 and $1,139,815 at May 31, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

Statement of Cash Flows

Statement of Cash Flows

 

Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU on March 1, 2019 with no material impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 and additional ASUs are now codified as Accounting Standards Codification Standard (“ASC”) 842 - Leases (“ASC 842”). ASC 842 supersedes the lease accounting guidance in ASC 840 Leases and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. It also requires additional disclosures about leasing arrangements. The Company adopted ASC 842 on March 1, 2019 and used the modified retrospective transition approach and did not restate its comparative periods. As of the date of implementation on March 1, 2019, the impact of the adoption of ASC 842 resulted in the recognition of a right of use asset and lease payable obligation on the Company’s consolidated balance sheets of $2,360,787. As the right of use asset and the lease payable obligation were the same upon adoption of ASC 842, there was no cumulative effect impact on the Company’s accumulated deficit.

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.

 

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Organization and Basis of Presentation (Tables)
9 Months Ended
May 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Foreign Currency Translation, Exchange Rate Used

The following table details the exchange rates used for the respective periods:

 

    May 31, 2019     May 31, 2018     August 31, 2018  
Period end: CAD to USD exchange rate   $ 0.7395     $ 0.7712     $ 0.7647  
Average period: CAD to USD exchange rate   $ 0.7540     $ 0.7901          

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
May 31, 2019
Accounting Policies [Abstract]  
Schedule of Estimated Useful Lives of Assets

Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

 

  Leasehold improvements 5 years
  Clinical equipment 5 years
  Computer equipment 3 years
  Office equipment 5 years
  Furniture and fixtures 5 years

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Accounts Receivables, Net (Tables)
9 Months Ended
May 31, 2019
Receivables [Abstract]  
Schedule of Accounts Receivables, Net

Accounts receivables, net at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Trade receivables   $ 1,571,743     $ 1,564,180  
Amounts earned but not billed     286,615       237,892  
      1,858,358       1,802,072  
Allowance for doubtful accounts     (475,329 )     (464,527 )
Accounts receivable, net   $ 1,383,029     $ 1,337,545  

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Other Receivables (Tables)
9 Months Ended
May 31, 2019
Receivables [Abstract]  
Schedule of Other Receivables

Other receivables at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019 (currently in default)   $ 277,312     $ 286,763  
Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020     29,580       30,588  
Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019     73,950       76,470  
Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022     55,463       57,352  
Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020     225,924       -  
Total other receivables     662,229       451,173  
Current portion     (577,186 )     (393,821 )
Long-term portion   $ 85,043     $ 57,352  

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment (Tables)
9 Months Ended
May 31, 2019
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Leasehold Improvements   $ 444,449     $ 372,010  
Clinical equipment     274,395       269,741  
Computer equipment     21,890       22,636  
Office equipment     26,658       24,658  
Furniture and fixtures     38,315       39,620  
      805,707       728,665  
Accumulated depreciation     (387,410 )     (328,344 )
Total   $ 418,297     $ 400,321  

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets (Tables)
9 Months Ended
May 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31, 2019     August 31, 2018  
Land use rights   $ 21,600,000     $ -  
Software license     758,567       -  
      22,358,567       -  
Accumulated amortization     -       -  
Total   $ 22,358,567     $ -  

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Expenses (Tables)
9 Months Ended
May 31, 2019
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31,     August 31,  
    2019     2018  
Accrued liabilities   $ 57,856     $ 266,123  
Accrued payroll     119,291       106,761  
Other     30,861       11,114  
    $ 208,008     $ 383,998  

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable (Tables)
9 Months Ended
May 31, 2019
Debt Disclosure [Abstract]  
Schedule of Notes Payable

Notes payable at May 31, 2019 and August 31, 2018 consisted of the following:

 

    May 31, 2019     August 31, 2018  
Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019. Currently in Dispute.   $ 369,750     $ 382,350  
      369,750       382,350  
Current portion     (369,750 )     (382,350 )
Long-term portion   $ -     $ -  

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Tables)
9 Months Ended
May 31, 2019
Leases [Abstract]  
Schedule of Lease Related Assets and Liabilities

The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of May 31, 2019:

 

    Classification on Balance Sheet   May 31, 2019  
Assets          
Operating lease assets   Operating lease right of use assets   $ 2,201,893  
Total lease assets       $ 2,201,893  
             
Liabilities            
Current liabilities            
Operating lease liability   Current operating lease liability   $ 413,896  
Noncurrent liabilities            
Operating lease liability   Long-term operating lease liability     1,789,779  
Total lease liability       $ 2,203,675  

Schedule of Lease Obligations

Lease obligations at May 31, 2019 consisted of the following:

 

Twelve months ending May 31,      
2020   $ 575,245  
2021     573,476  
2022     464,407  
2023     401,394  
2024     197,454  
2025     149,001  
Thereafter     412,330  
Total payments     2,773,307  
Amount representing interest     (569,632 )
Lease obligation, net     2,203,675  
Less lease obligation, current portion     (413,896 )
Lease obligation, long-term portion   $ 1,789,779  

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Deficit (Tables)
9 Months Ended
May 31, 2019
Equity [Abstract]  
Schedule of Stock Option and Warrant Activity

The following is a summary of stock option/warrant activity:

 

                Weighted        
          Weighted     Average        
    Options/     Average     Remaining     Aggregate  
    Warrants     Exercise     Contractual     Intrinsic  
    Outstanding     Price     Life     Value  
Outstanding, August 31, 2018     10,030,000       0.30       4.56     $ 7,045,500  
Granted     75,000       0.95                  
Forfeited     (10,000 )     2.00                  
Exercised     -                          
Outstanding, May 31, 2019     10,095,000       0.30       3.83     $ 9,573,000  
Exercisable, May 31, 2019     10,095,000     $ 0.30       3.83     $ 9,573,000  

Schedule of Options and Warrants Outstanding and Exercisable

The exercise price for options/warrants outstanding at May 31, 2019:

 

Outstanding and Exercisable  
Number of     Exercise  
Options/Warrants     Price  
  5,500,000     $ 0.16  
  1,000,000       0.32  
  50,000       0.33  
  120,000       0.40  
  2,000,000       0.42  
  100,000       0.50  
  1,000,000       0.62  
  250,000       0.80  
  75,000       0.95  
  10,095,000          

Schedule of Fair Value of Options Granted by Using Valuation Assumptions

The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through May 31, 2019, are as follows:

 

Risk-free interest rate     2.78 %
Expected life of the options     3.5 years  
Expected volatility     294 %
Expected dividend yield     0 %

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Organization and Basis of Presentation (Details Narrative) - USD ($)
9 Months Ended
Apr. 25, 2017
May 31, 2019
May 31, 2018
Number of restricted shares of common stock   3,245,444  
Common stock issued in connection with reverse merger transaction     $ 233,155
Parent Company [Member]      
Common stock issued in connection with reverse merger transaction   $ 6,904  
Turbine Truck Engines, Inc [Member]      
State country name   Delaware  
Date of incorporation   Nov. 27, 2000  
NHL [Member] | Share Exchange Agreement [Member]      
Number of restricted shares of common stock 167,797,406    
Percentage of common stock issued and outstanding 85.00%    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) - CAD [Member]
May 31, 2019
Aug. 31, 2018
May 31, 2018
Period End [Member]      
Foreign currency exchange rate 0.7395 0.7647 0.7712
Average Period [Member]      
Foreign currency exchange rate 0.7540 0.7901
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2019
May 31, 2019
Aug. 31, 2018
Allowance for uncollectible accounts receivable $ 475,329 $ 475,329 $ 464,527
Impairment of its long-lived assets  
Goodwill 584,205 584,205 604,113
Refundable acquisition deposits 1,445,495 $ 1,445,495 1,112,404
Potentially dilutive common stock options and warrants outstanding, shares   10,095,000  
Translation gains 1,102,188 $ 1,102,188 1,139,815
Right of use asset 2,201,893 2,201,893
Lease payable obligation 2,203,675 2,203,675  
ASC 842 [Member]      
Right of use asset 2,360,787 2,360,787  
Lease payable obligation 2,360,787 2,360,787  
Cumulative effect on retained earnings    
Apka Health, Inc. [Member]      
Goodwill 369,750 369,750  
Executive Fitness Leaders [Member]      
Goodwill $ 214,455 $ 214,455  
Land Use Rights [Member]      
Intangible asset, useful life amortized over term   50 years  
Software License [Member]      
Intangible asset, useful life amortized over term   7 years  
Novo Healthnet Kemptville Centre, Inc. [Member]      
Equity method investment, ownership percentage 80.00% 80.00%  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)
9 Months Ended
May 31, 2019
Leasehold Improvements [Member]  
Property and equipment, estimated lives 5 years
Clinical Equipment [Member]  
Property and equipment, estimated lives 5 years
Computer Equipment [Member]  
Property and equipment, estimated lives 3 years
Office Equipment [Member]  
Property and equipment, estimated lives 5 years
Furniture and Fixtures [Member]  
Property and equipment, estimated lives 5 years
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Related Party Transactions (Details Narrative) - USD ($)
Jan. 31, 2018
May 31, 2019
Aug. 31, 2018
Related Party Transactions [Abstract]      
Due to related parties   $ 931,128 $ 1,116,261
Related party debt, converted amount $ 813,125    
Debt converted, shares issued 1,976,483    
Debt conversion, description The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.    
Debt conversion price $ 0.4114    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Receivables [Abstract]    
Trade receivables $ 1,571,743 $ 1,564,180
Amounts earned but not billed 286,615 237,892
Accounts receivable, gross 1,858,358 1,802,072
Allowance for doubtful accounts (475,329) (464,527)
Accounts receivable, net $ 1,383,029 $ 1,337,545
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Other Receivables - Schedule of Other Receivables (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Total other receivables $ 662,229 $ 451,173
Current portion (577,186) (393,821)
Long-term portion 85,043 57,352
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]    
Total other receivables 277,312 286,763
Advance to Corporation One [Member]    
Total other receivables 29,580 30,588
Advance to Corporation Two [Member]    
Total other receivables 73,950 76,470
Advance to Corporation Three [Member]    
Total other receivables 55,463 57,352
Advance to Corporation Four [Member]    
Total other receivables $ 225,924
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Other Receivables - Schedule of Other Receivables (Details) (Parenthetical)
9 Months Ended 12 Months Ended
May 31, 2019
Aug. 31, 2018
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]    
Percentage of interest accrued per annum 8.00% 8.00%
Notes receivable due date Mar. 01, 2019 Mar. 01, 2019
Advance to Corporation One [Member]    
Notes receivable due date Nov. 18, 2020 Nov. 18, 2020
Advance to Corporation Two [Member]    
Percentage of interest accrued per annum 12.00% 12.00%
Notes receivable due date Sep. 30, 2019 Sep. 30, 2019
Advance to Corporation Three [Member]    
Percentage of interest accrued per annum 10.00% 10.00%
Notes receivable due date May 01, 2022 May 01, 2022
Advance to Corporation Four [Member]    
Percentage of interest accrued per annum 10.00%  
Notes receivable due date Feb. 07, 2020  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment (Details Narrative) - USD ($)
9 Months Ended
May 31, 2019
May 31, 2018
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 71,256 $ 52,287
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Property and equipment, gross $ 805,707 $ 728,665
Accumulated depreciation (387,410) (328,344)
Total 418,297 400,321
Leasehold Improvements [Member]    
Property and equipment, gross 444,449 372,010
Clinical Equipment [Member]    
Property and equipment, gross 274,395 269,741
Computer Equipment [Member]    
Property and equipment, gross 21,890 22,636
Office Equipment [Member]    
Property and equipment, gross 26,658 24,658
Furniture and Fixtures [Member]    
Property and equipment, gross $ 38,315 $ 39,620
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets (Details Narrative) - USD ($)
9 Months Ended
May 31, 2019
May 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Intangible assets, gross $ 22,358,567
Accumulated amortization
Total 22,358,567
Land Use Rights [Member]    
Intangible assets, gross 21,600,000
Software License [Member]    
Intangible assets, gross $ 758,567
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Payables and Accruals [Abstract]    
Accrued liabilities $ 57,856 $ 266,123
Accrued payroll 119,291 106,761
Other 30,861 11,114
Accrued expenses $ 208,008 $ 383,998
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable - Schedule of Notes Payable (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Notes payable $ 369,750 $ 382,350
Current portion (369,750) (382,350)
Long-term portion
Notes Payable [Member]    
Notes payable $ 369,750 $ 382,350
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - Notes Payable [Member]
9 Months Ended 12 Months Ended
May 31, 2019
Aug. 31, 2018
Percentage of interest accrued per annum 0.00% 0.00%
Notes payable, due date Mar. 27, 2019 Mar. 27, 2019
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Debentures, Related Parties (Details Narrative)
Jan. 31, 2018
USD ($)
$ / shares
shares
Dec. 02, 2017
Sep. 30, 2013
CAD ($)
May 31, 2019
USD ($)
Aug. 31, 2018
USD ($)
Nov. 30, 2017
USD ($)
Debentures, outstanding       $ 1,224,000  
Accrued interest       $ 188,321 $ 156,121  
Debt converted, shares issued | shares 1,976,483          
Debt conversion price | $ / shares $ 0.4114          
Debt conversion, description The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.          
Five Debentures [Member]            
Debentures, outstanding           $ 4,968,990
Debt interest rate     8.00%      
Debt due date     Sep. 30, 2016      
Debt extended due date   Sep. 30, 2019        
Five Debentures [Member] | CAD [Member]            
Debentures, outstanding     $ 6,402,512      
Debentures [Member]            
Debentures, outstanding $ 3,894,809          
Percentage of debt converted 75.00%          
Accrued interest $ 414,965          
Debt converted, shares issued | shares 10,475,872          
Debt conversion price | $ / shares $ 0.4114          
Debt conversion, description The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.          
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
May 31, 2019
May 31, 2019
May 31, 2018
Leases [Abstract]      
Operating leases expiration date   2028  
Lease expense $ 142,676 $ 98,316
Amortization expense 98,316    
Interest expense 44,360    
Cash paid under operating leases $ 115,311    
Weighted average remaining lease terms 6 years 6 years  
Weighted average discount rate 8.00% 8.00%  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Schedule of Lease Related Assets and Liabilities (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Leases [Abstract]    
Operating lease assets $ 2,201,893
Total lease assets 2,201,893  
Current liabilities- Operating lease liability 413,896
Noncurrent liabilities - Operating lease liability 1,789,779
Total lease liability $ 2,203,675  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Schedule of Lease Obligations (Details) - USD ($)
May 31, 2019
Aug. 31, 2018
Leases [Abstract]    
2020 $ 575,245  
2021 573,476  
2022 464,407  
2023 401,394  
2024 197,454  
2025 149,001  
Thereafter 412,330  
Total payments 2,773,307  
Amount representing interest (569,632)  
Lease obligation, net 2,203,675  
Less lease obligation, current portion (413,896)
Lease obligation, long-term portion $ 1,789,779
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Deficit (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Jan. 16, 2018
Sep. 08, 2015
May 31, 2019
May 31, 2018
Aug. 31, 2018
May 30, 2019
Convertible preferred stock, shares authorized     1,000,000   1,000,000  
Convertible preferred stock, par value     $ 0.001   $ 0.001  
Convertible preferred stock, shares issued     0   0  
Convertible preferred stock, shares outstanding     0   0  
Common stock, shares authorized     499,000,000   499,000,000  
Common stock, par value     $ 0.001   $ 0.001  
Common stock, shares issued     223,585,536   207,881,743  
Common stock, shares outstanding     223,585,536   207,881,743  
Number of restricted shares issued     3,245,444      
Proceeds from issuance of restricted shares     $ 3,228,098      
Stock options granted weighted-average grant date fair value         $ 0.39  
Stock options/warrants weighted-average exercise price         $ 0.40  
Stock option expense     70,846 $ 1,220,419    
Unamortized stock option expense     $ 0      
August 31, 2019 [Member]            
Stock options granted weighted-average grant date fair value     $ 0.94      
Stock options/warrants weighted-average exercise price     $ 0.95      
2015 Incentive Compensation Plan [Member]            
Number of shares available for future grant           4,987,500
2015 Incentive Compensation Plan [Member] | Maximum [Member]            
Number of common stock shares issued   5,000,000        
2018 Incentive Plan [Member]            
Number of common stock shares issued 10,000,000          
Number of shares available for future grant     9,875,000      
Joint Venture Agreement [Member]            
Number of restricted shares issued     12,000,000      
Proceeds from issuance of restricted shares     $ 21,600,000      
Shares issued price per share     $ 1.80      
Licensing Agreement [Member]            
Number of restricted shares issued     458,349      
Proceeds from issuance of restricted shares     $ 758,567      
Shares issued price per share     $ 1.655      
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details)
9 Months Ended
May 31, 2019
USD ($)
$ / shares
shares
Equity [Abstract]  
Options/Warrants Outstanding, Beginning Balance 10,030,000
Options/Warrants Outstanding, Granted 75,000
Options/Warrants Outstanding, Forfeited (10,000)
Options/Warrants Outstanding, Exercised
Options/Warrants Outstanding, Ending Balance 10,095,000
Options/Warrants Outstanding, Exercisable 10,095,000
Weighted Average Exercise Price, Outstanding, Beginning Balance | $ / shares $ 0.30
Weighted Average Exercise Price, Granted | $ / shares 0.95
Weighted Average Exercise Price, Forfeited | $ / shares 2.00
Weighted Average Exercise Price, Outstanding, Ending Balance | $ / shares 0.30
Weighted Average Exercise Price, Exercisable | $ / shares $ 0.30
Weighted Average Remaining Contractual Life, Outstanding, Beginning Balance 4 years 6 months 21 days
Weighted Average Remaining Contractual Life, Outstanding, Ending Balance 3 years 9 months 29 days
Weighted Average Remaining Contractual Life, Exercisable 3 years 9 months 29 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance | $ $ 7,045,500
Aggregate Intrinsic Value, Outstanding, Ending Balance | $ 9,573,000
Aggregate Intrinsic Value, Exercisable | $ $ 9,573,000
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details)
May 31, 2019
$ / shares
shares
Number of Options/Warrants, Outstanding 10,095,000
Number of Options/Warrants, Exercisable 10,095,000
Exercise Price Range One [Member]  
Number of Options/Warrants, Outstanding 5,500,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.16
Number of Options/Warrants, Exercisable 5,500,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.16
Exercise Price Range Two [Member]  
Number of Options/Warrants, Outstanding 1,000,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.32
Number of Options/Warrants, Exercisable 1,000,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.32
Exercise Price Range Three [Member]  
Number of Options/Warrants, Outstanding 50,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.33
Number of Options/Warrants, Exercisable 50,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.33
Exercise Price Range Four [Member]  
Number of Options/Warrants, Outstanding 120,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.40
Number of Options/Warrants, Exercisable 120,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.40
Exercise Price Range Five [Member]  
Number of Options/Warrants, Outstanding 2,000,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.42
Number of Options/Warrants, Exercisable 2,000,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.42
Exercise Price Range Six [Member]  
Number of Options/Warrants, Outstanding 100,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.50
Number of Options/Warrants, Exercisable 100,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.50
Exercise Price Range Seven [Member]  
Number of Options/Warrants, Outstanding 1,000,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.62
Number of Options/Warrants, Exercisable 1,000,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.62
Exercise Price Range Eight [Member]  
Number of Options/Warrants, Outstanding 250,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.80
Number of Options/Warrants, Exercisable 250,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.80
Exercise Price Range Nine [Member]  
Number of Options/Warrants, Outstanding 75,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares $ 0.95
Number of Options/Warrants, Exercisable 75,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares $ 0.95
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)
9 Months Ended
May 31, 2019
Equity [Abstract]  
Risk-free interest rate 2.78%
Expected life of the options 3 years 6 months
Expected volatility 294.00%
Expected dividend yield 0.00%
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent Events (Details Narrative) - USD ($)
9 Months Ended
Jun. 04, 2019
May 31, 2019
Number of restricted shares sold   3,245,444
Purchase price of restricted shares   $ 3,228,098
Subsequent Event [Member] | Accredited Investor [Member]    
Number of restricted shares sold 21,413  
Purchase price of restricted shares $ 22,269  
EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 132 323 1 false 49 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://novointegrated.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://novointegrated.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://novointegrated.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://novointegrated.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://novointegrated.com/role/StatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://novointegrated.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Basis of Presentation Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Related Party Transactions Sheet http://novointegrated.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Receivables, Net Sheet http://novointegrated.com/role/AccountsReceivablesNet Accounts Receivables, Net Notes 10 false false R11.htm 00000011 - Disclosure - Other Receivables Sheet http://novointegrated.com/role/OtherReceivables Other Receivables Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment Sheet http://novointegrated.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Intangible Assets Sheet http://novointegrated.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses Sheet http://novointegrated.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 00000015 - Disclosure - Notes Payable Notes http://novointegrated.com/role/NotesPayable Notes Payable Notes 15 false false R16.htm 00000016 - Disclosure - Debentures, Related Parties Sheet http://novointegrated.com/role/DebenturesRelatedParties Debentures, Related Parties Notes 16 false false R17.htm 00000017 - Disclosure - Leases Sheet http://novointegrated.com/role/Leases Leases Notes 17 false false R18.htm 00000018 - Disclosure - Stockholders' Deficit Sheet http://novointegrated.com/role/StockholdersDeficit Stockholders' Deficit Notes 18 false false R19.htm 00000019 - Disclosure - Commitments and Contingencies Sheet http://novointegrated.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://novointegrated.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Organization and Basis of Presentation (Tables) Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentationTables Organization and Basis of Presentation (Tables) Tables http://novointegrated.com/role/OrganizationAndBasisOfPresentation 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Accounts Receivables, Net (Tables) Sheet http://novointegrated.com/role/AccountsReceivablesNetTables Accounts Receivables, Net (Tables) Tables http://novointegrated.com/role/AccountsReceivablesNet 24 false false R25.htm 00000025 - Disclosure - Other Receivables (Tables) Sheet http://novointegrated.com/role/OtherReceivablesTables Other Receivables (Tables) Tables http://novointegrated.com/role/OtherReceivables 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Tables) Sheet http://novointegrated.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://novointegrated.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Intangible Assets (Tables) Sheet http://novointegrated.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://novointegrated.com/role/IntangibleAssets 27 false false R28.htm 00000028 - Disclosure - Accrued Expenses (Tables) Sheet http://novointegrated.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://novointegrated.com/role/AccruedExpenses 28 false false R29.htm 00000029 - Disclosure - Notes Payable (Tables) Notes http://novointegrated.com/role/NotesPayableTables Notes Payable (Tables) Tables http://novointegrated.com/role/NotesPayable 29 false false R30.htm 00000030 - Disclosure - Leases (Tables) Sheet http://novointegrated.com/role/LeasesTables Leases (Tables) Tables http://novointegrated.com/role/Leases 30 false false R31.htm 00000031 - Disclosure - Stockholders' Deficit (Tables) Sheet http://novointegrated.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://novointegrated.com/role/StockholdersDeficit 31 false false R32.htm 00000032 - Disclosure - Organization and Basis of Presentation (Details Narrative) Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentationDetailsNarrative Organization and Basis of Presentation (Details Narrative) Details http://novointegrated.com/role/OrganizationAndBasisOfPresentationTables 32 false false R33.htm 00000033 - Disclosure - Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentation-ScheduleOfForeignCurrencyTranslationExchangeRateUsedDetails Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) Details 33 false false R34.htm 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesTables 34 false false R35.htm 00000035 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfEstimatedUsefulLivesOfAssetsDetails Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) Details 35 false false R36.htm 00000036 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://novointegrated.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://novointegrated.com/role/RelatedPartyTransactions 36 false false R37.htm 00000037 - Disclosure - Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) Sheet http://novointegrated.com/role/AccountsReceivablesNet-ScheduleOfAccountsReceivablesNetDetails Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) Details 37 false false R38.htm 00000038 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) Sheet http://novointegrated.com/role/OtherReceivables-ScheduleOfOtherReceivablesDetails Other Receivables - Schedule of Other Receivables (Details) Details 38 false false R39.htm 00000039 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) (Parenthetical) Sheet http://novointegrated.com/role/OtherReceivables-ScheduleOfOtherReceivablesDetailsParenthetical Other Receivables - Schedule of Other Receivables (Details) (Parenthetical) Details 39 false false R40.htm 00000040 - Disclosure - Property and Equipment (Details Narrative) Sheet http://novointegrated.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://novointegrated.com/role/PropertyAndEquipmentTables 40 false false R41.htm 00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://novointegrated.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 41 false false R42.htm 00000042 - Disclosure - Intangible Assets (Details Narrative) Sheet http://novointegrated.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://novointegrated.com/role/IntangibleAssetsTables 42 false false R43.htm 00000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://novointegrated.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 43 false false R44.htm 00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://novointegrated.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 44 false false R45.htm 00000045 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://novointegrated.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 45 false false R46.htm 00000046 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://novointegrated.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 46 false false R47.htm 00000047 - Disclosure - Debentures, Related Parties (Details Narrative) Sheet http://novointegrated.com/role/DebenturesRelatedPartiesDetailsNarrative Debentures, Related Parties (Details Narrative) Details http://novointegrated.com/role/DebenturesRelatedParties 47 false false R48.htm 00000048 - Disclosure - Leases (Details Narrative) Sheet http://novointegrated.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://novointegrated.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - Leases - Schedule of Lease Related Assets and Liabilities (Details) Sheet http://novointegrated.com/role/Leases-ScheduleOfLeaseRelatedAssetsAndLiabilitiesDetails Leases - Schedule of Lease Related Assets and Liabilities (Details) Details 49 false false R50.htm 00000050 - Disclosure - Leases - Schedule of Lease Obligations (Details) Sheet http://novointegrated.com/role/Leases-ScheduleOfLeaseObligationsDetails Leases - Schedule of Lease Obligations (Details) Details 50 false false R51.htm 00000051 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://novointegrated.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://novointegrated.com/role/StockholdersDeficitTables 51 false false R52.htm 00000052 - Disclosure - Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) Sheet http://novointegrated.com/role/StockholdersDeficit-ScheduleOfStockOptionAndWarrantActivityDetails Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) Details 52 false false R53.htm 00000053 - Disclosure - Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details) Sheet http://novointegrated.com/role/StockholdersDeficit-ScheduleOfOptionsAndWarrantsOutstandingAndExercisableDetails Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details) Details 53 false false R54.htm 00000054 - Disclosure - Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details) Sheet http://novointegrated.com/role/StockholdersDeficit-ScheduleOfFairValueOfOptionsGrantedByUsingValuationAssumptionsDetails Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details) Details 54 false false R55.htm 00000055 - Disclosure - Subsequent Events (Details Narrative) Sheet http://novointegrated.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://novointegrated.com/role/SubsequentEvents 55 false false All Reports Book All Reports nvos-20190531.xml nvos-20190531.xsd nvos-20190531_cal.xml nvos-20190531_def.xml nvos-20190531_lab.xml nvos-20190531_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 71 0001493152-19-010490-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-010490-xbrl.zip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end